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VSEBINA
STANDARDS AND FUTURE PERSPECTIVES IN SYSTEMIC TREATMENT OF OESOPHAGO-
GASTRIC CANCER (Cervantes)
THYROID CANCER (Elisei)
GERM_CELL TUMoRs (šłruinc)
M ETASTATIC cAsTRATIoN - RESISTANT PRoSTATE cAN cE R (šeľuga)
NEUROENDocRINE TUMoRs. LUNG NET (čufer)
LYMPHOMAS IN PATIENTS WITH HIv INFEcTIoNs (Gregoľič' HoruaĘ Mesti, Jezeršek
Novaković)
MALIGNANT PLEURAL MEsoTHELIoMA (unk, Ribnikar, Goličnik' Zakotnik)
MALIGNANT PLEURAt MEsoTHELIoMA. CLINICAL cAsE REPoRT (Ribnikar, Goličnik, Unk,
Juvan, Zakotnik)
ADRENAL GLAND TUMoRs (DevjaĘ ovčariček, StrojniĘ Boľštnar)
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STANDARDS AND FUTURE PERSPECTIVES IN
SYSTEMIC TREATMENT OF OESOPHAGO.GASTRIC
CANCER
í:Ť ĐĘ
*:JI
7
:_ ĘlJ' r -"--'
ril
ffiĚlg
il
.|-ľtsFl-l-ľřl_l F-li
:o'+ ;t-l FltsFl lr-l
Ftlfr:EEĘ:'_
irr,
lL
i
I
_l_
I
L
I
. Suľgical ľesection
. Pathology assessment and estimation of risk
. Treatment based upon classical TNM stage
. Postopeľative Chemotheľapy of limited
value
. Postopeľative Chemoľadiation
CLASSICAL APPROACH TO
LOCALISED GASTRIC CANCER
1
META-ANALYSIS OT TRIALS INVOLVING
ADJUVANT CHEMOTHERAPY VERSUS
SURGERY ALONE FOR GASTRIC CANCER.I
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FĘuĺr 3. oveľall Suľlval Esümate After Any Chemotľrcapy or Surgery Alone Truncated at
í0 Years
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.LIMITED VALUE, IF ANY
.HRs BY O.9O
.NON SIGNIFICANT EFFECT IN MOST SINGLE TRTALS
.BUT...
-NONSTANDARDIZED SURGERY
-MANY SINGLE TRIALS UNDERPOWERED
-HYPOTETIC BEN EFIT OVERESTIMATED
-STRATIFIED BY MANY AND DIFFERENT CLINICAL OR
PATHOLOGICAL FACTORS
-HETEROGEN EOUS POPULATION ACCRUED
-N NEGATIVE PATIENTS PREDOMINATE
-SELECTED POPULATION OF PATIENTS WELL ADAPTED TO
TOTAL OR PARTIAL GASTRECTOMY
-BIOLOGICAL PREDICTIVE FACTORS UNKOWN AND
THEREFORE NOT APPLIED TO STRATIFICATION
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Figure 1. overall survival among All Eligiblo Patlents, Accord- FlguÍ. 2. Rol8psg.'reg suÍviv0l 8mong All Ellglblo P8tignts, Ac_
ino to Tr@tment_Group Asionment' cordĺng to Tl@tmont-Group As8ignmgn|s.
Clear benefit in disease free and oveľall suľvival with median follow-up of 6
yeaľs. Risk reduction ofdeath by 24o/o.
Type ofsuľgery: D2 resection less than 107o
Planning of Radiation to be modiÍied afteľ central review in 357o of cases due
to minoľ/minor deviations
McDonald JS et al (N Engl J Med 2001;345:725-30.)
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. Efficacy of treatment used is unknown
. Treatment appears to be less well tolerated after
major surgery
' Commencement of post-operative treatment
may be delayed by slow recovery from surgery
or peri-operative morbidity
. lmportant morbidity related with total
gastrectomy, specially altered nutritional status
I
STAGING AND RESECTABILITY SATUS
RESECTABLE
LOCALISED
UNRESECTABLE
ADVANCED OR METASTATIC
I ł
RO RESECTION RATE 50% RESECTION IS R1.R2
MEDIAI\I SURVIVAL
30 MONTHS
S-Y-SURVIYALz 30o/o
MEDIAII SURVIVAL
8 MONTHS
S-Y_SURVIY !ĺLz<SoÄ
LOCALISED GASTRIC CANCER:
Estimated medĺan suľvival 10-14 months
RATIONALE FOR PRE.OPERATIVE TREATMENT
. Tumour downstaging/downsizing prior to surgery
. Reduction of microscopic marginal involvement with
tumour
. lncrease likelihood of curative resection
. Eliminating disseminated micrometastatic
disease and achieving systemic control
. Demonstrates in vlvo sensitivity to systemic
treatment
. lmprovement of tumour related symptoms
. Better tolerated than post-operative therapy
. More patients may benefit from therapy
I
. Risk of progression of disease during pre-
operative treatment
. ?!ncreased risk of peri-operative morbldity
. Pathological staging is difficult after a response
to pre-operative treatment
. Need for alternative prognostlc or predictive factors
' Definltlve surgery may be delayed if signiflcant
toxicity occurs
. Patients must be referred for treatment prior to
surgery
D Cunningham, W Allum, S Stenning and S Weeden
on behalf of the UK NCRI Upper Gl Glinical Studies Group.
Gonducted by the UK Medical Research Councll GTU.
NEJM 2006' 355(ĺ): íí-20
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Ellgible patlents:
. Adenocarcinoma of the stomach
or lower third of the oesophagus
(from 'ĺ 999)' suitable for curative
resection
. Non-métastatic disease
. Stage ll or greater
Primary
Ôverall survival
Secondary
Progression-Íree su rviVal
Surgical resectability
Quality of Life
Chemotherapy (ECF):
Epirubicin 50mg/m2' lV day í
cisplatin 60mg/m2' lV day'ĺ
s-FU 200mgl m2lday, continuous
infusion, days 1-21
(cycles repeated every 3 weeks)
Recruitment: July 1994-April 2002
cunningham ét al NEJM 2006
S arm
N=253
CSC arm
N=250
3-6 weeks
6-12 weéks
Post-opeľative chemotherapy:
EGFx3
Surgery
s Pre-operative chemotherapy
ECFx3
Study entry and randomization
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csc
N=250
s
N=253
*f-
Commenced pre-operative
chemotherapy
N=237 (95%)
_-I__
Completed pre-operative
chemotherapy
N=215 (86%)
_!=
Proceeded to surgery
N=219 (88%)
Proceeded to surgery
N=240(95%)
Cunningham et al NEJM 2006
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csc
N=250
Proceeded to surgery
N=219 (88%)
!
Commenced post-operative
chemotherapy
N=137 (55%)
!
Completed post-operative
chemotherapy
N=104 (42Yo)
cunningham et al NEJM 2006
100%94TOTAL
5%5Other
40/4Hickman line complications
60/06Toxicity from pre-op chemotherapy
10%oIPost-op complications
12o/o11Patient request
11o/o10Surgery but did not complete pre-op chemo
52o/o
15Never had surgery
34Early death/ progression of disease
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Preop Postop
Granulocytes
Lymphocytes
WBC Count
Haemoglobin
Plateleb
Haemotological other
24o/o
20o/o
12%
5o/o
< 1o/o
< 1o/o
28o/o
17o/o
11o/o
1%
3o/o
2%
Preop Poatop
Nausea
Vomiting
Neurological maximum
Skin
Stomatitis
Diarrhoea
60/o
60/o
4o/o
3%
4o/o
3o/o
12o/o
10%
4o/o
2o/o
4o/o
4%
No significant difference in toxicity between pre-operative and post-operative treatment.
Cunningham et al NEJM 2006
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csc s
Postopeľative deaths 60/o
(14t21e)
460/o
60/o
(15t240)
Postoperative compl ications 460/o
Median duration of
post-operative hospita! stay
13 days 13 days
Cunningham et al NEJM 2006
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csc s p-value
Maximum tumour diameter
Median (lQR) 3.cm 5.0cm
(2.0-5.0) (3.5-7.5)
<0,001, Mann-
Whitney U test
Extent of tumour (gastric only)
T1tT2 52%
T3ft4 48%
38o/o
62%
0.009, t(2 test (trend)
Nodal status (gastric only)
NO/N1
N2/N3
84%
16%
760/o
29o/o
O,O1 , x2 test (trend)
Cunningham st al NEJM 2006
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Logrank p-value = 0.000ĺ
Hazaľd Ratio = 0.66
(95% Cl 0.53 - 0.81)
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Overall
Logrank p-value = 0.009
Hazard Ratio = 0.75
(950/o Cl 0.60 - 0.93)
EvontsTotal
.163 250 
- 
csc
1S0 253'--s
EvonlśTotáĺ
119 250
170 253 .-..s
1224il4
Months Írcm randomlstion
72
Monlhs llom mndomissllon
On multivariate analysis,
treatment effect unchanged after
adjustment for age, performance
status, site of primary and gender
Hazard ratio for death
. Adjusted: 0.74 (95%Cl: 0,59-
0.93)
. Unadiusted: 0.75
4mo13%9o/oBoneÍlt to csc
ařm
20 mo23o/o41%s
24mo36%50%csc
Modlan
surylval
6 yeaľ
surulvel
2 y.ear
Eulvlval
*lncluded relapse, PD and death from any cause. Cunningham et al NEJM 2006
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In operable gastric and lower oesophageal
cancer, perioperative chemotherapy:
. leads to downsizing of primary tumour
. significantly improves progression-free
survival
. significantly improves overall survival
Cunningham et al NEJM 2006
Median survival 27 months35 months20 months24 months
5 year suľvival 260/o*40Yo*23o/"36%
50o/o2 year survival 50%*58%*41%
Peri-op chemo
+ surgery
N=250
Surgery only
N=277
Post-op
chemoRT +
surgery
N=282
Surgery only
N=253
MAGt6i (N=503) INT1í62 (N=556)
Direct comparison of results is difficult due to different inclusion
criteria and different time of randomization.
ĺ Cunningham NEJM 2006
2 MacDonald NEJM 2001; 2004 Gl Cancers Symposium *Estimated from curve
1 5
Randomization N=224
cr+s I I s
Within 4 weeks
4 - 6 weeks
ł
Regecüon
ł _ e l"""lo
Resecüon
Follow-up
*S-Fluorouracll 800 mg/m2 dí-5*
+ Cisplatin í00 mg/m2 day ĺ
Tľial accrual 1995-2003
Median FU 5.7 yrs
BOIGE et aIASCO 2007
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on multivarlate analysi8, tľoatment
effect unchanged afteľ adjustment
Íor agé' performance status, 8lte of
pľimaĺy and gender
Progno3tlc variables ln Cox
multivarlate analysls:
. Pľeoperatlve GT
. Gastric locatlon
9mo,140/o10%Benoflt to CSC
arm
20 mo24%47%Surgery
29 mo380/58%Perlop CT
Medlan
suľvlval
5 yoar
surulval
2year
surulval
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SUMMARY OF TRIALS OF PERIOPERATIVE
CHEMOTHERAPY FOR LOCALIZED GASTRIC
CANCER
113111
No CT
CDDP
5.FU
Boige
ASCO 2007
250253
No CT
ECFCunningham
NEJM 2006
HR
(CI at
es%)
5-yeaľ
Suľvival
CT
S-yeaľ
Suľvival
Control
Nľ.
Pts
CT
Nľ.
Pts
Contľol
CTTrial
FUTURE DIRECTIONS IN THE TREATMENT OF
LOCALISED GASTRIC cAlľCER
- More active systemic treatment combinations,
including taľgeted theľapies
_ Defining ľole of ľadiotherapy in ľelation to
systemic theľapy
- Diagnostic/assessment
_ Assessing ľesponse to treatment (ĺ.e. role of PET)
_ Tľanslational: pľognostic and predictive maľkers
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_ Impľoved coordination of caľe
_ To consideľ each case from a vaľiety of peľspectives.
_ Patĺents aľe moľe likely to be offeľed a ľange of types of
tľeatment at appľopriate tĺmes
_ A supportĺve envĺľonment where professionals can shaľe
theĺr concerns
_ Suľgeons ľeceive feedback from histopathologĺsts and other
team membeľs on the ľesults of theiľwork
_ optĺmal settĺng for clĺnĺcal research
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. I)iscussion of all new cases before surgery
. I)ĺscussĺon of ĺmaging data to deteľmÍne optĺmal stagĺng
. Selection of patĺents foľ pľeoperatĺve theľapy
. Dĺscussĺon of pathology repoľt, stľessĺng on the assessment of
resected lymph nodes after location
. Selectĺon for postoperatĺve theľapy
. Detaĺled dĺscussĺon of any ľelapse duľĺng follow up
. Yearly audĺts of all activitĺes and results
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. Clĺnical assessment and staging
. Multidisciplinaľy team dĺscussion
r Pľeoperative tľeatment in all patients wĺth clinical
stage II and III
. Suľgical ľesection after chemotheľapy
. Pathology assessment and estĺmation of ľisk
r Postopeľative chemotheľapy?
r Paľticipation in tľĺals
21
NEOADJUVANT CHEMOTHERAPY
IN GASTRIC CANCER: CONCLUSIONS
. Peľiopeľative Chemotheľapy:
- Induces downstaging
- May ĺncľease the R0 ľesection ľate
- Pľolongs disease fľee suľvival
_ Improves oveľall suľvĺval
. Evidence level I based upon 2 well designed and pľopeľly
conducted randomized trials
. Pľeopeľative theľapy is better tolerated than postoperative
. Locallized gastľic canceľ ľequiľes a multĺdisciplinary team
appľoach
. Fuľther ľeseaľch on biological predictive factors ĺs needed
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Fundación lnve3tlgsción
ClÍnlco de Valoncia
inchĽa
HAVE WE MADE ANY PROGRESS IN THE
TREATMENT OF ADVANCED GASTRIC
CANCER?
A. CERVANTES
HOSPITAL CLINICO
UNIVERSITY OF VALENCIA
SPAIN
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Current Questions in Advanced
Gastric Cancer Management
Which are the aims of theľapy?
Should patients with advanced gastric cancer ľeceive
chemotherapy and when?
Which are the main prognostic factors?
ls primary tumor location relevant for tľeatment
decisions?
Which aľe the active drugs?
ls theľe any standard combination of drugs?
Why haven't we been successful in getting better
treatment for this disease?
Which are the aims of therapy?
Symptomatic control
lmprove QoL or avoid its deterioration
Delay tumor progression
Prolong survival
23
Favors ch€motherapy
10
20
51
30
21
52
Hazard Rallo (Íixgd)
No.
0.ĺ 0.2 0.5
103 81
cnomolhorapy Bśic
Total (95% Cl) 0.39, 0.28 to 0.52
Sludy 95% Ct
Tost Íoľ h8tologgneity: x'?= 3.32, (P = .1 9}
Teol Íor ovorall eÍÍecl: z = 6.1 5 (P <
1.0 2.0 5.0
Favors BSC
--_-|-.*-
--*-
Murad 1993e
Ęĺhonen 199510
Scheithauer 1996lĺ
0.3iI, 0.17 to 0.64
0.25, 0.13 to 0.47
0.49, 0.3lÍ} lo 0'74
Wagner A, et al. JCO 2006
Should patients with advanced gastric
cancer receive chemothe rapy?
When should patients with advanced
gastric cancer receive chemothe rapy?
INITIAL ELF-FULV DELAYED CT AT PD
Glimelius B, et al. Ann Oncol 1994.
4 MONTHS1O MONTHSSURVIVAL
25%o70%
82 DAYS8 DAYSTIME TO CT
1000/,CT 50%
QOL
IMPROVEMENT
24
0 I 2 3 4 5 6 7 I 9 lO ll 12 13
Time since randomisation (years)
Figure 3. oveľall survival according to pľimary tumour origins'
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ls primary tumor location relevant for
treatment decisions?
Chau l, et al. Ann Oncol 2009
I
PS2
Liver mets
Peritoneal mets
t Alkaline Phosphatase
Chau l, et al. J Clin Oncol 2004.
ain prognosticWhat are the
factors?
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What are the main prognostic
factors?
Group Score median os 1_yeaľ Surv
Chau I, et al. J Clin Oncol 2004.
4.1 m 11.0%
7.4 mModerate 1 o 2 25.7%
11.8 m 48.SYo
Pooľ 3o4
Good 0
Table ĺ. Multivariate Baseline Prognostic Model for REAL 2 Study Patients
Factor Hazard Ratio 99o/o Cl P
Performance status
0-1
2
Liver metastasis
Peńtoneal metastasis
Alkaline phosphatase = 100 U/L
'l
2-O4
1.473
1.546
1.',!14
1.533 to 2.725
1 .219 to 1 .779
1.212 to 1.971
O.923 to 1.345
<.000'l
<.0001
<.0001
.14
Chau I, et al. J Clin Oncol 2009.
What are the main prognostic
factors?
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Chau l, et al. J Clin Oncol 2009
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_ Good Íisk
. Moderate ńsk
- Poor risk
|_year suĺvival (95% Cl)
52.ł% |17.8to 56.7)
33.1% 120.3to 36.01
13.796 (8.9to 'l9.41
Loo_ľank P<.000t
Median survival
12.7 months
8.6 monńs
ł.3 months
n
Ą8I
t,073
t8t
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Which are the active drugs?
5-Fluorouracll
Oral Fluoropirymidines (capecltabine, S1,
u FT)
Anthľacyclines?
Cisplatin
Oxaliplatin
Docetaxel
cPT-11
Tľanstuzumab
culllnan í9851a
Dc Llôl ĺ986Đ
Lovl 19864
Cullinan l9o4rs
LoohÍor ĺ994'!
coluccl ĺ985l'
Barcre 1998lô
Yamamura ĺ998ż
Popov 20o2!r
OhtBu 20o3ro
Boucta 20(xĺ7
5l
42
94
ĺ83
E4
35
06
37
3o
175
89
836
5ĺ
43
93
69
94
3ô
36
34
30
105
45
€Ńl6
o.9o' 0.61 to ĺ.33
1.16, 0.26 to 5.15
0.54, 0.43 to 0.77
0.9O, 0.69 lo 1.1 6
0.85,0.61 to 1.19
0.70, 0.42 to 1. !8
0.89. 0.55 to f .il2
0.88, 0.55 to 1.41
0.86, 0.32 to 2.29
1.04, 0.82 to 1.32
0.85, 0.45 to 0.95
FavoB Slnglc Aocnt
HeaÍd Ralio
a
+
-.+
combimtim singlÔ-Ąsnt
No.
1.0 2.O 5.O
0.43, 0.74 to 0,93
95%cl
0.1 0.2 0.5
FavoÍ' comblnallon
Total (959a Cl)
Tcđ loľ hđ.rogcn.lty: r'= l2.3o, (P- .27)
Toll bľ owÍall óÍíoct: Z = 3.28 (P = .001)
Wagrrer A, et al. JCO 2006.
Monotherapy or combination of drugs?
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What are the active drugs that have
shown superiority in randomized trials?
5-Fluorouľacil
Oral Fluoropirymidines (capecitabine, S1,
u FT)
Anthracyclines?
C is platin
Oxa liplatin
Docetaxel
cPT-11
Transtuzumab
SPIRITS. Study Design
S-1: 40-60 mg BID for 2.8 days q6wks
S-1:40-60 mg BlD Íor21 days qSwks
CDDP: 60 mg/mz iv on day I
Koizumi W, et al. Lancet Oncol 2008
S-1 + CDDP
Iil
AGC
S-1 alone
No pľior
Chemo.
Central Randomization l
(dynamic balancing)
Adjustment Factors:
o lnstitule
.PS
o Unresectable vs Recurrent
29
1
2L
10
35
23
51
43
8o
77
x5
6
t2x
ro7
20
A
o
100
80
Numbeľat ľisk
5_1andcisPlatĺn 1.48
s-1gÍoup 150
- 
S-1 andcisplatingroup
- 
s-1 gľoup
HR=o.Z/;9596 Cl0 61-0.98; p=o.o4
*-šbo
E'ž
!
Tt
Ô
S-1plus cisplatin Versus S_1 alone foľfirst-linetreatment of
hase llltrialcancer :aPIRITS trialadvanced
Koizumi W, et al. Lancet Oncol 2008
Docetaxe!-based chemotherapy in advanced
gastric cancer: Phase lll trial
. Measurable/evaluable
metastatic or rneasurable
locally recurrent gastric
adenocarcinoma
. Age >18 years
. KPS >70
. Adequate haematological/
biochem ical parameters
. No prioľ palliative
chemotherapy
R
A
N
D
o
M
I
s
A
T
I
o
N
Van Cutsem E, et al. J Clin Oncof,p006
Treatllellt tllltiI PD' Col.lsent WithdľaWn or
lrnacceptable toxicity: tLilTlortr assesslnents qBw
CF
cisplatin 'ĺ00 mg/m2 over 1-3 h. Day 'ĺ
s-FU '1000 mg/m2lday over 5 days, q4w
( n=230)
DCF
Docetaxel 75 mg/m2 over 1 lr, Day 'ĺ
Cisplatin 75 mg/rn2 over 1-3 h. Day I
5-FU 750 mg/m2/clay over 5 days. q3w
(1't=227)
30
100
Be0
80
^70Ń
;60
tso.Í'940o
0 3330276912
30
20
t0
DCF +
Median:9.2 rĺ}onths
CF - -r"
Median: 8.6 months
Log-rank P = .02
,til15 18 21 24
Time (months)
Docetaxel-CF vs CF in advanced gastric
cancer: overall survival
Van Cutsem E, et al. J Clin Oncol 2006
ĺ00
80
s
>- 60
=.o(!
-ct 40o
CL
20 - DCFCF
Log-rank P = .009
03691215182'.12427
Time (months)
Docetaxe!-CF vs CF in advanced gastric
cancer: Time to definitive Karnofsky PS
deterioration
AjaniJA, et al
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Sro
E: 60
-cI 5UG
€40
ł30
20
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ĺ1
5
0
ĺ00
755
21 24
Time (months)
17
I
No. of patlonts stlll at ľisk
DCF 184 94
cF 200 90
47 29
35 16
HB = 1.445 (95% Cl, 1.082 10 1.929)
Rlsk reduction = 30.8%
Log-renk P- .0121
- DCF cFMedian (months) 6.5 4.2
Events 85 (46%) 104 (52%)
36912
Docetaxel-CF vs CF in advanced gastric
cancer: Time to 5% definitive Global
Health status deterioration
Ajani JA, et al. J Clin Oncol 2007
Phase lll' ľandomized, opelr-|abel, international, nrulticenter study
. Stratrfrcationfactors
aclvanced vs metastatic
GC vs GEJ
rrreasurable vs non-nreasurable
ECOG PS 0-1 vs 2
capecrtabrne vs 5-FU
B.]l]q el aI At)stlac| 45ĺ)6 ASC() :00!]
ToGA trial design
Clrose.n at rnvestrgator s dtscretron
GEJ gaStloesopl]aqeŕ]l Jtll)ctloll
H ER2-positrve
aclvanced GC
in=584)
3807 lratients screened i
B10 HER2-posltive ĺ22'] 'I'l
32
Primary end point: OS
0 2 4 6 B 1012 141618202224262830 323436
Time (months)
Van Cutsem E, et al. ASCO 2009 abstract 4509T trastuzumab
11 1
0.60, 0.91
95% Ct
Event
21 13
1Ą 1
294 277 2Ą6 209 1;3 147 113 90
29A 266 223 185 143 11; 90 64
No.
at risk
;1 56 43 30
47 32 24 16
126410
6s000
1.0
09
0B
o7
06
05
o4
03
02
0.1
00
'- FC+1
'"FC
13.8
11.1
167
182
Median
Events OS
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CR CoÍnplete response PR partial response
ORR= CR + PR
ORRPR
n.
p=0.001 7
CR
0
p=0.0599
.t0
30
:0
10
F+C + tĺaStL]zunlab
F+C
lntent to treat
p=0.01 45
Patients 60
('fo)
50
Secondary end point:
tumor response rate
HERI: LEssoNs ľ'RoM BREAST CANCER
_ HER2 is oveľ-expľessed in 15-250/" of patients and ĺndicates
pooľ pľognosĺs
- HER2 status is defined by ICH or FISH
_ In HER2 positive patientso tľastuzumab is actĺve as single
agent and in combĺnation with CTl, in advanced disease
and in the adjuvant setting2-3
_ Tľastuzumabo when given concurľently with
anthľacyclĺnes, incľeases caľdiotoxocĺty to 27o/o, but can be
given after anthracyclines wĺth a betteľ safety Pľofile3-ł
lVogel et al., JCO 2002; 2Slamon et al., NEJM 200'l; 3Smith et al., Lancet 2007;
4Romond et al., NEJM 2005;
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HERA H í year
83í / N9831 AG->PH
BCIRG 006 AC.>DH
BCIRG 006 DGarboH
FinHerA VH / DH.>CEF
l--H
l+
t-+-{
F{-.{
#
Median follow-up,
years
1
2
2
2
3
0 Favors
Trastuzumab
í Favoĺs no 2
Trastuzumab
HR
Piccart-Gebhart et al 2005; Romond et al 2005;
Slamon et al 2005; Joensuu et al 2006
EBG trials
[1-year
HerceptinJ Arm n
Asymptomatic
LVEF decline, %a
Seveľe
cHF,%
Cardiac
death, n
HERAb
NSABP B-31
NccTG N983ĺ
BCrRG 006
H 1 year
AC!PH
AC!PH
AC!DH
DcaľboH
1678
947
570
1068
ĺo56
3.O
NR
NR
ĺ8.0
8.6
o.6
3.gcum [5 yr)
3.3cum [3 yr]
1.9
o.4
o
o
0
o
o
EBG, early bľeast cancer; LVEF, left ventricular
ejection fraction; cHF, congestive heaľt failure;
cum, cumulative incidence; Carbo, caľboplatin
.Data not compaľable due to different
assessment cľiteľia; b1-year median follow-up
Slamon et al 2006;
Rastogi etal2OOT;
Smith et al 2OO7; Perez et al 2OOB
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Efficacy: OS by HER2 status
R s'n ĺJtlt)
Exploratory analysis
Subgroup
F t-t
N
,:rł : |
Fd'.,ors T FJ\r|)ĺ s l]o T
lllLlr-r,.' l, I lSll.
lH(;.1.'t lSll1 .', lfl(l
Illíj:'F SH-
rHc r-i Frstl.
lHc:-'Ftsll.
[]0-:. FrsH+
ll]c_: . /ĺ l_ŚH
Hazata 'r5' . Cl
IaÍ|c
ĺl4ecJlan oS
ĺ llloĺlth S i
Ail
Pre-planned analysis
OPTIMAL THRESHOLD DEFINING HER-2
STATUS
_ In the exploľatory pooled analysis of patients with
ICH 3* and ICH 2+ with FISH *ve, median oveľall
suľvival incľeased to 16 months fľom 11.8 months
- Those cľiteria aľe similaľ to those ľecommended in
breast canceľ guidelinesl
_ In ToGA, only 50Á of eligible patients had ICH 2
oľ 1+ with FISH negative2
_ Magnitude of the benefit of tľastuzumab could be
gľeateľ than observed in ToGA tľial if those
guidelines to define HER2 status weľe applied to
gastľĺc canceľ
1 Wolff et al., JCO 2007;2 et al. ASCO 2008
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IIERjl: LEssoNs FROM BREAST cAI\ľcER
- HER2 is oveľ_expľessed in 15-250Á of patients and indicates
pooľ pľognosis
- HER2 status ĺs defined by ICH oľ FISH
_ In HER2 positive patientso transtuzumab ĺs active as sĺngle
agent and in combĺnatĺon with CTlo in advanced disease
and ĺn the adjuvant setting2-3
_ Tľanstuzumabrwhen given concurľently with
anthracyclĺnes, incľeases caľdiotoxocĺty to 27o/o, but can be
given after anthľacyclines with a betteľ safety Profile3-ł
lVogel et al., JCO 2002; 2Slamon et al., NEJM 2001; 3Smith et al., Lancet 2007;
4Romond et al., NEJM 2005;
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ToGA TRIAL: TOXICITY DERIVED FROM THE
ADDITION OF TRANSTUZUMAB
- No increase in hematological oľ GI toxiciĘ
- No incľease in clinicaly detected caľdiac events,
but a higher ľate of asymptomatic decľease of
LVEF (4.6% vs 101 7o)
_ The median duration of tľanstuzumab tľeatment is
shoľteľ than in bľeast canceľ tľials ( 4.9 months)
- CaľdiotoxiciĘ might be more pľevalent when used
in other settings (peľioperative, with
anthľacyclines oľ afteľ second line theľapy)
The HERs,
- 
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The epidermal growth factor family of receptors comprises
4 transmembrane proteins with distinct propertĺes, which all regulate cell
proliferation
Extracellular
HEB4HERl
HERSHER2
NRGz
NRGl
a4
.q-
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a
Adapted from Tzahar and Yarden' Biochim Biophys Acŕa' 1998;1377:Nĺ25.
lntracellular
ąR
The HER signallrng network
Yarden Y. Sliwkowski M. Nat Rev Mol Cell Biol 2001:2:127-37
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The HER signalling network (cont'd)
Yarderr Y. Sliwkowski M. Nat Rev Mol Cell Biol 2001:2:127-37
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The HER signalling network (cont'd)
Yaľden Y. Slĺwkowski M. Nat ReV Mol Cell Biol 2001:2|127-37
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The HER signalling network (cont'd)
Yarden Y, Sliwkowski M. Nat Rev Mol Cell Biol 200'liZ:127-37
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_ MECHANISMS OF RESISTANCE TO
TRANSTUZUMAB
. PRESENCE oľ'HER2 c TERMINAL ľ'RAGMENTS
(p9sHER;l)
. INCREASED SIGNAL F'ROM EGF'RIERBB3
. PTEN LOSS OF FUNCTION AND ACTIVATION OF
THE PI3K AKT n-TOR PATHWAY
. LATERAL SIGNALING BY OTHER RECEPTOR
F'AMILIES
BASELGAJ AND SWAIN SM CANCER NAT REV 2OO9
HIGH EXPRESSION OF HER3 !S ASSOCIATED WITH
A DECREASED SURVIVAL IN GASTRIC CANCER
A HER.I B HER2
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HAYASHI M, et a!. CIin Gancer Res 2008
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HIGH EXPRESSION OF HER3 IS ASSOCIATED WITH
A DECREASED SURVIVAL IN GASTRIC CANCER
c
HER3
100
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It.#ř+*+s-+ł
low expression (n=55)
high expression (n=79)
p=0.0000
0 1000 2000 3000
Time after surgery (days)
HAYASHI M, et al. Clin Cancer Res 2008
What are the active drugs that have
shown non inferiority in randomized
trials?
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REAL-2: First line phase 3 trial in
oesophagogastric ca ncer
Primary end point of demonstrating non-
inferiority in both PPP comparisons for
survival was met (upper limit of Cl of
HR<1.23)
Lt.2EOX
ĹYrMed, mo
No. (ITT) oRR, o/o
244
Arm
os
46.80/o 47.9o/a
Cunningham et al, NEJM 2008
ECF
ECX
EOF
EOX
ll'I- 1 002
PPP=96 1
HR foľ ITT population : 0.88 (0.77 * |
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p= 0.058
No. at Risk
Fluorouľacil 481
Capecitabine 480
L2
Yearc since Randomization
REAL-2: overa!l suľvival
fluoropyrimidin comparison
Cunningham et al, NEJM 2008
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HR for lTT population = 0.9í (0.79-1.04)
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B Platinum Comparison
30
Cisplatin
Oxaliplatin
p=0.í59
No. at Risk
Cisplatin
Oxaliplatin
L2
Yearc since Randomization
REAL-2: Overall survival
platinum compaľison
Cunningham et al, NEJM 2008
HR: 0.80 (95% CI: 0.66-0.97)
Log rank p=0.02
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REAL-2: Overall survival: ECF vs EOX
comparison
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EstiÍneted pĺobatilĘ
HR=0.85 (95% Cl: 0.64-í.r3}
coíÍlp!íld to HR uppcr lamil 1'25' pro.00€
- 
xP (n=139)
-- FP 1n=ĺ37)
Median OS
moÍrths (95% cl}
10.5 (9.3-11.?)
9,3 (7.4-10.61
s.FU CDDP VERSUS CAPECITABINE.CDDP.
A RANDOMISED PHASE III
NONr N FERIORITY TRIAL (M L1 7 0321
Kang YK et al, Ann Oncol 2009
oveľall Suľvival by Tľeatment (ITT)
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HR:0.87 (95% Cl: 0,77-098, P=0.006)
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s.FU VERSUS CAPECITABINE
A META.ANALYSIS OF REAL2 AND ML17O32
Okines AFC et al, Ann Oncol 2009
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5-FU. LV. Oxaliplatin (FLO) vs 5-FU, LV, Cisplatin
(FLP) in Advanced Gastroesophageal Adenocarcinoma
J2() 1llrticrlts rr itll lltlr lttlcctl gltstI'ic cllllcťl'
Al-Batran SE et al, J Clin Oncol 2009
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OXALIPLATIN VERSUS CISPLATIN
A RANDOMISED PHASE III TRIAL OF FLO VS FLP
PROGRESSION FREE SURVIVAL
Al-Batran SE et al, J Clin Oncol 2009
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Al-Batran SE et al, J Clin Oncol 2009
Irinotecan and Gastric Cancer
Many phases II studies:
r Anti-tumoral activity in gastric cancer
r Usually combined with 5FU
' Good safety profile
One large randomized phase II study (LV5FU2 vs
LV5FU2 - Platine vs FOLFIRI):
. In favour of FOLFiRI regimen (RR, PFS, OS, tolerance)
One large phase III study (IF vs Platine-5FU):
r Non inferiority of IF vs PF
BoLlché o et al J Clin oncol 2004 22 4319 4328
Dank M et al Anr.r Oncol 2008.19(8):1450-7
Cuĺran D et al Qtlal' L|fe Res 2009.18:853'61
CPT'I'l usually done in CRC (FOLFIRI)
Well klrown and managed drug
47
Mesurablo or not
PS wHo0-'l or 2
Adj (R)CT or not
Linitis oÍ not
Cardial or gaskic
Contor
B: FoLFIRI unťlprogresslon ; tnen ECX zo line
R
A
stratiÍication
ECX until prosression ; tnen FOLFIRI zo line
EcX : D1 = Epirubkjn 50 mďm, (15 mh'), osplaün 60 mďm, (1 h) ; D2 b 15 : ąpđltablne 1 o/mz x2ld' Đ1 = D21cfud & ď EdMn < N ryh, (ffix r8 ffi)
FoLFIRI I D1 = IrimEan 180 mgim, (90 mln) + LV 400 mgy'm, (2h), 5R b 400 mo/mr, sFu c'l' 2400 mďm, (46h)' Dl = D14
. Objective I : lst line Time to Treatment Failure (TTF)
Time between
Randomisation and:
í/ Progression
Or 2/ tt discontinuation
Or 3/ Death
R Guimbaud et al, ESMO 2010
95
, QLQC3ĺ et sTo-22
, Data not Śhom
. Objectives ll : - PFs, os, (TTF 2d rine)
- Toxicity,
- Response rate, QoL*
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Arm A (ECX 1st line) : 5.29 m. [4.53;6.31]
Arm B (FOLFIRI l.rline) : 5,75 m. [5.1e; 6.74]
P (Log-rank)= 0.96
HR (B vs A)= 0.99 [0.81; 1.21]
209 135
207 142
0.95
1'01 Ĺ0.82i 1'24|
Arm A (EcX 1st ĺine) : 9.49 m. [8.77; 11'14]
Arm B (FoLFlRl 18l line) : 9'72 m'ÍB'u 11.27|
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Transtuzumab + Chemotheľapyo
HAVE WE MADE ANY PROGRESS IN
THE TREATMENT OF ADVANCED GASTRIC CANCER?
MEDIAN OVERALL SURVIVAL IN ADVANCED GASTRIC CANCER
'1. Wagner A, et al. JCO 2003, 2. van Cutserr E, et al. JCO 2006. 3.Kang YK et al,
Ann Oncol 2009.4. Al Batran SE, et al. JCO 2009. 5. Cr,rnningham D, et al. NEJM 2007
6.van Cutsen E. et al. ASCO 2009.
5-FU monotherapyl
Best
supportive
caľe1
49
chemotherapy vs Bscí
ToGAz
HAVE WE MADE ANY PROGRESS IN
THE TREATMENT OF ADVANCED GASTRIC CANCER?
ABSOLUTE INCREASE IN MEDIAN SURVIVAL IN ADVANCED GASTRIC CANCER
1. WagnerA,etal.JCO2003.2.Kaizumi W,etal,LancetOncol 2008.3vanCutsenE,et
al. JCO 2006. 4.Kang YK et al, Ann Oncol 2009. S. Al Batran SE, et at. JCO 2009.
6. Cunningham D, et al. NEJM 2007. 7.van Cutsen E, et al. ASCO 2009.
HAVE WE MADE ANY PROGRESS IN
THE TREATMENT OF ADVANCED GASTRIC CANCER?
RISK OF DEATH REDUCTION IN ADVANCED GASTRIC CANCER
1. Wagner A. et al. JCO 2003, 2. van Cutsen E, et al. JCO 2006. 3.Kang yK et al,
Ann Oncol 2009.4. Al Batran SE, et al. JCO 2009. 5. Cunningham D, et al. NEJM 2OO7
6.van Cutsen E, et al. ASCO 2009.
HR:0.85 p=0.008
HR: 0.80 p=0.02
Colll lri l'latloll vs lllĺlllołllĺ:ľĺt|'ly l
Chemotheľapy Vs Bsc1
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lnoperable locally
advanced or
metastatic cancer of
stomach or GEJ
(n=7741
XP* + b.vaclzumab
7.6mg/kg q3w
AVAGAST: first phase lll randomised trial
with bevacizumab in gastric cancer
o Primary endpoint: OS
o Secondary endpoints:
PFS, TTP. oRR, duration of respolrse. saíety, QoL, biomarkers
XP = capccital]inclclsl)|atinI GEJ = gastÍocsophagcal JUlrctlot] http://clinicaltÍi.rls'n"",",r,'n".,*älťl1?l"ui';
'5-FU also allovr'od
Capecitabrn{r 1.000 rnq/nlr bid. (iays 1- 21
Cisplatin B0 ilrq/nr'. day 1
ĺMaxinrunl oÍ 6 cyclcs of cisplatiÍ]
capccitabiĺrf] anrl l)oVaciŻUlnab/placcbo Ll11til PD
Stľatif ication factors
1. Geographic region
2. Chelnotherapy backbone
3. Disease status
Secondary endpoints: PFS and RR
Tinle (lrrołlths)
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Primary endpoint: OS
Time (months)
12
0.2
C)
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12.1
1.0
63 'l5 'ĺ B 21 24
:r- -
- 
XP + bevacizumab
0.4
0.6
Xp + placebo
HR=0.87 (95% Cl: 0.73-1 .03)
p=0.1 002
GASTRIC CANCER: SECOND LINE
CHEMOTHERAPY
lľinĺltccan \'eľsus lrest suppoľtir'c caľe (I}sC') as 2nĺl-line
thcrap1' in gastľic canceľ
Arm A lrinotecan 250 mg/m'q3w (1st cycle)to be
increased to 350 mg/m', depending on
toxicity.
Arm B BSC
l2() paticnts planncĺl tĺl lrc incluĺlccl
Tľial clĺlscd ĺluc tĺl pĺlĺlľ ilccľuill (ł() prrticnts in 5{) nlĺlnths)
Thuss-Patience PC et al, ECCO/ESMO 2009 abstr 6504
52
lrino: n = 21 ,21 events, median = 4.0 mths
BSC: n = 19, '19 events, median = 2.4 mths
test: P = 9.923
Cl: 0.25 - 0.
1.0
days
0.0
0.2
0.8
0 40 80 120 160 200 240 280 320
c,
E o,o
6
ř5
o o.4
Overall survival (lTT-Population)
Thuss-Patience PC et al. ECCO/ESMO 2009 abstr 6504 /:I.tlffi
Recommended approach to
advanced gastric cancer patients
Select patients with PS0-1 to participate in
clinical trials
CT should have a palliative role
Patient reported otcomes of value
Assess the risk of toxicity vs benefit
TCF, ECF, EOX, XP or similar schedules of
value
Consideľ second line therapy foľ selected
patients. More trials on this point aľe
needed
53
Recommended approach to improve
results on gastric cancer patients
Design better clinical trials within
academic and community centers
I nternational Cooperation
Biological agents should be studied in
randomized trials
Further studies on better predictive and
prognostic biomarkers
. Radiology: Maľta Rausell
. Pathology: Samuel Navarro
. Suľgeľy: FemandoLőpez, Roberto Maľtí, Blas Floľ,
Salvador Lledó, Vicente Tarrazona
. Radiation Oncology: Ana Heľnanďez, Pepe Lőpez
Toľľeci11a
. Medical Oncology: Desamparados Roda, Alejandro
Pérez-Fidalgo, Susana Roselló' Andľés Cervantes
MULTIDISCPLINARY TEAM FOR GASTRO-
ESOPHAGEAL CANCER
UNIVERSITY HOSPITAL VALENCIA
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Rossella Elisei
Deportment of Endocrĺnology, Uníversity Hospitol, Piso. Italy
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sYMPOSIUM
RARE TUMORS
THYROID CANCER IS RARE TUMOR
AND REPRESENT5 ONLY I% OF ALL HUMAN TUMORS
I All human
cancer
Thyroid cancer
1
THYROID CANCER HI5TOTYPE
(Deportment of Endocrinology, Píso)
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PAPILLARY THYROID CARCINOMA
T-ýPTI AL NUCLEAR FEATURES
o GooĎ cYToLoGTcAL DIAoNosIs 9
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THYROID TUMORIGENESIS: MOLECULAR EVENTS
Meto-onolysis (2003 -2OO7) of
in thyroid tumors:
Prevolence ĺn different hystotypes
<t"L <17" 0 45% 20%
H-Ros * 5% 34% 45% 157"" 5%
PÁX-8/PPAR9 " o 7% 30% tl% o
+BRAF
0 30%
FTC PTC PDC ond
ATC
5%
Benign F A
nodules
RET/PTC * 5-tO% 5%
4
Kaplan-Meier su ľYival analysis
Elisei R et al. JCE&M 2008
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RADIATION AND THYROID CANCER
The Chernobyl Experience ĺ&
b
Thyroid concer in Belorus bef ore ond
gfŤer the Chernoby! occident
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Ćordis E et ol. J. Rodiol Prot 26: 727-74o. 2006
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Estimoted risk of developinq thyroid cąncer
after rodiotion dose of Ĺ' GÝ, bý level of soil
íodine ond potossium iodide śuppl'ementotion ot
the' time of Chernobyl'<iccident
3.5 (1.8 to 7.o) 10.8 (5.ó to 20.8)*
From Ćordis E et ol' J Notl Concer Inst- 97: 724 32. 2oo5
**Highest risk
Yes 3.3 (1.o to 10.6)
oR ot 1 GV Q5% cr)
No
HĺghesŤ two tertiles
of soil iodine
Consumption of
potossium iodide
Lowest tertiles
of soĺl ĺodine
PREVALENCE OF THYROID NODULES AND
THYROID CANTER IN 2 SICILIAN AREA5
WITH DIFFERENT IODINE CONTENT
from Belfiore A, Cancer 1987
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PTC AND FTC PREVALENCE BEFORE AND AFTER
IoDINE PRoPHyLÁXIs IN AUsTRIA
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AGE AT DIÁoNosIs
IN PAPILLARY AND FOLLTCVLAR THYROID CANCER
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MAXIMUM TUMOR SIZE
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... thyroid concer ĺncidence, in
France, hos dromoticolly increosed
over the lost 2 decades.
The increosed incidence ĺs 8. 1 % and
ó.2 % per year in femoles ond moles
Laurence Leenhardt et aĺ, Thyroid, 2oo4
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Popillory thyroid cancer
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Thyroĺd Nodule
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Are the Clinĺcol ond Pothologicol Feotures oÍ
Ďifferentioted Thyroid Corcinomo Reolly Changed
ove? the Lost 35 Yeors? Study on 4t87 Potients
from o 5in9!e ltolion Instĺtution to Answer this
Question
Rossello Elisei," Eleonoro Molinoro,* Louro Agate, Volerĺo
Bottĺci, Lucio Mosserinĺ, Cloudio Ceccąrelli, Froncesco Lĺppĺ,
Lucĺo Grąsso, Fulvio Bosolo, Generoso Bevilocquo, Poolo
Miccolĺ, 6ioncorlo Di Coscio, Pqolo Vittĺ, Furio Pocĺni, ond
Aldo Pinchero
J Clin Endocrinol iĄetab. 2o1o
Ghanging features of thyroid tumors
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Changing features of thyroid tumors
Nodulor Goiter
Autoim Thyroiditis
Groves' diseose
Toxic Ádenomo
Neck irrodiotion
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Changing features of thyroid tumors
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Changing features of thyroid tumors
Tumor size: N*
I cm (mPTC)
>1 cm 2 cm
>2 cm ,4 cm
4cm
Locol extension: N*
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1990-2004
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(16.s%)
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p
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.O 0001
Changing features of thyroid tumors
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(ó1 37.)
764
(19 1%)
655
(16 47")
1?6
(3 2%)
3726
1 354
(36.0)
3662
730
(le e%)
7?13
415
(34 2%\
Ĺ?r3
66
(5.47")
7702
542
(49 ?%)
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(so. 1 7")
1ó3
(14 87")
65
(5.e%)
896
283
(31 5%)
873
134
(15 3%)
2971
666
(22.4%)
2971
67
(2%)
?893
1908
(65 e%)
432
(14 9v")
492
(17 %)
ó1
(2 2%)
2830
1077
(37 8?"')
2789
596
(21 4?")
o 0001
0.0008
.0 0001
Ďistant Metostoses: N*
.0 0001
Lymph nodes metostoses: N*
(De 6root's
I
II
III
IV
Multifocolity: N*
Biloterolity: N*
.0 00Ol
<0.0001
NS (0.1)
.0.0001
Ćlinicol Ćlosses
clossificotion): N*
4ra4
1081
(25 8%)
4784
127
(s%)
3995
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? mojor considerotions:
Fĺnding of smoll popillory thyroíd concer
(ond of other chonging feotures) os conseguence
of the widespreod use of neck ultrosound
\ onticipotĺon of diognosís \
Increosed percentage of less odvonced tumors
(both for lymph nodes ond dístont metostoses)
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SURVIVAL OF DTc PATIENTS (N=4t87) AFTER
A LON6 TERM FOLLOW UP OF 35 YEARS
(Elisei R et oĺ, JĆE&M, 2010)
Follow up (years)
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Survivol of DTC potĺents wĺth ond wĺthout
distont metostoses of the diognosis
Deportment of Endocrinology, UniversiĘ of Piso
4187 ĎTc from L969 to 2oo4
051015202530
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Iodine
20-30% of thyroid corcinomos lose the copociÍy
to uptoke ĺodine
No Uptoke of Iodine
1 31 -I useless
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10-year survival after chemotherapy, external Rx or both
(Dept. of Endocrinology, Pisa)
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OVERALL RESULTS OF CHEMOTHERAPY
VÁRIoU5 coMBINATIoNs oF DIFFERENT DRU65
PRoDUCE sI^ĄILAR RE5PoN5E RATES (2o-3o%),
WITH SYMPTOMATIC IMPROVEMENT IN SOME
PÁTIENTS BUT No BENEFIT oN THE SURVIVAL
RATE
THE REsPoNsEs ARE USUALLy PARTIAL ÁND
SHORT-LIVED.
THE ToXIcrTy oF THE DRU6S I5 UsUÁLLy VERy
HT.GH
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onđ!D, sk'mb|' lh}mil, hej rld
nđk' 8stlic' bMdcĹ Eüa| ild
pacrĺic caca, CÍSľ, ÍE|em,
güobhĺurą mpllm lyqńmr
Kiđlcy. liwĘ bEt' Fosłate, |b&
owiu' @brcbl, thymil' hąd !!d
nćk' BđÍic and poctiic Úcđ,
clsT' mlmÍla tlióhltflną
lymphomĄ ląú.mia
Kiůéy' tt8t' lD& Érvi6|, liwĺ'
lhyftŕd' pđal lnd coloÉbI crE.Ĺ
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clinicll Ťtivity rĺúJor íudyTÚ8.t llLę of dcwbĺnĚnlA!Éil
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(B^Y4390üĺ:
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đlEr ca€ś
cĺcđ
ď tll fÚ
vEcm.2, -1,
PDcFn' náĺ KlT
IECFR.ĺ'.l .3'
pmFR, Kn,
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ApľoEd foť lidEy
!M cĺsT. r'ha$ ll
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Smhinib
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ĺ99' l00|
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Anti-angiogenĺc tyrusine kinase ĺnhibitĺlrs: rYhat is theĺľ
mechanism of action? KľĹJtv.l.(;othk.Hmklt.w.vffhd
l0.l(lfi/śl0|!6{n9.9
THERAPEUTIC TARoETS
BRÁF poant mutotions
RAS point mutotion
RET/PTC reą?rongeľnent
VEOFR, PDOFR, etc..
RAS poĺnt mutotion
PAX8 - PPÁRy reorrongement
VEOFR. PD6FR, etc..
Folliculor Ćorcinomo
Popillory Ćorcinomo
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PHASE II STUDY: Potĺent oÜ1l
Liver Metostosis of thyľoid Concer
-::.::--t't
Kindly provĺded by Dr l4/ells 5, Duke Universiŕy, USA
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I PHASE fI STUDY: Potient OOl:
Lymph Node MetosŤosis of thyroid concer
Kindly provided by Dr l,1/eĺĺs S. Duke Universlty. USA
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PHASE II STUDY: Potĺent oo2
Breost Metostosis of thyroid cancer
Kindly provided by Dr Wells S, Duke Universĺty, USA
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Folliculor thyroid concer : braĺn/bone metostosis
Erf,í.ĘĐ Trir{il
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ANAPLASTIC THYROID CANCER
AFTER 20 DAys oF THERÁPy
ÁFTER 10 DAys
BEFORE THERAPY
t
,t-
$ffi
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CONCLUSIONS
Thyroi concer ĺs o ro?e tumor but is the tumor
wiŤh the highest rote of increose in ĺncĺdence
With the exception of o significont increose of
smoll tumors, oll the other epidemĺologĺcol
feotures hove been mointoined over the yeors
The vost mojority is curoble with conventionol
theropy (i.e thyroidectomy ond 131-I
rodiometobolic theropy)
New theropeutĺc strotegĺes wĺth TKI ą?e under
investigotion f or the treoment of
odvonced/rodioĺodine ref ractory coses (15 - 20%
of oll coses): ve?y promising results!!
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GERM-CELL TUMORS
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r Germ-cell tumor type ll - most common solid malignancy of
Young Gaucasian men between 15 and 40 yearc of age
r The incidence in Europe rising, with doubling every 20 yearc
r Gurrent incidence 6.3 / í00 000 / year
r Highest incidence in Noľthern European countries 6.8 / ĺ00 00o
I year
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Byology of GTC ll - 5
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1
r cls
r Seminoma ( 50 % )
r Nonseminoma (40 %l
n Embrional carcinoma
n Teratoma
n Yolk sac tumor
n Choriocarcinoma
r Mixed germ celltumorc (10%l
llistopathology 2
o
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Normal testicle
5
I
Histopathology 3
Carcinoma in situ
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Seminoma
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Embrional carcinoma
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Mature teratoma
Yolk sac tumor
Choriocarcinoma
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Diagnostics and treatment
Testicular seminoma: ESMO Clinical Practice Guidelines
for diagnosis, treatment and follow-up
H.-J. schmollĺ, K. Jordan't, R. Huddart2, M. P. Laguna Pes3, A' Horuich2' K. Fizazi4 & V. Katajas
on behalf of the EsMo Guĺdelines Working Grouŕ
Annals of oncology 2í (Supplement 5): v140-v146,20'10
Testicular non-seminoma: ESMO Clinical Practice Guidelines
for diagnosis, treatment and follow-up
H..J. schmoll1, K. Jordaní, R' Huddańz' M. P. Laguna Pes3, A' Horuich2' K' Fizazi4 & V. Katajas
On behalf of the ESMO Guidelines Working Group.
Annals of Oncology 21 (Supplement 5): v147-v'154,20'10
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ln patients with advanced and rapidly progrcssive digease
- uľgent chemotheľapy mandatory - no Inicial orchiectomy
tr ýplcalclinicalpicture
tr marker elevatlon
pure claeic seminoma no AFP,
BHCG > 200 consldered a non-seminoma
Extrygonadal tumor syndrom
r Histology of testicular mass
n high tumor markerc
n biopsy
o Tranalngulnal orchyectomy
n Tegtls-conserulng suľgery
n No scrotal violation I
'.|lrx''r,',; /l' 1,,iľ,] ]',1' l 'Ii]|l !ĺr! 1l
Extrygonadal tumor syndrom
n retropeľytoneaI oľ medistinal mass
n high tumor markens
n biopsy
I undifferentiated (adeno)carcinoma of unknown primary
r tipicalTM elevation
r elevated copy numbeľ of cromogome i12p
( speclflc for germ cell tumorc )
r í/3 clS ln tostls
r {/3 bumod out tumor ( scar ln testlcular tl8rug (
r ĺ/3 defflnltlvepÍlmary extragonadal GcT wlthout aÍfectlng tho tostlclo
1 0
Diagnosis / staging / risk assessment 3
. blood tests
) differentiation of stage and IGCCCG prognostic group:
TM determined
. before orhlectomy
. 7 days after orhiectomy
T
Diagnosis / staging / risk assessment 4
Testlcular sonography of both testicles mandatory
11
CT scan abdomen, pelvis mandatory
Ct scan of chest mandatory
exeption pure seminoma stage I
1 2
ln case of borderline lymph node size, CT scan should be
repeated in 6 weeks to define definitive treatment strategy
If imaging is normal TM decline monitoring until normalization
MRI of CNS only in advanced stages or with symptoms
Bone scan in case of symptoms
PET scan - no contribution in early stages
a possible option in seminoma stage ll/ lll
for defining treatment strategies in case of
residual leseions
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t-ń{2 (>2ó 6)
Lb{l (r2đ)
nńnďFdbd
'B
rcÚ
Ęffiyď.ňve|/
lllwffitthĘň
hlŇ&łlĺ6ńh
nrcMoíblunE
ĘlŃ
rD
Ú
D|&!nl' ffioÚl
ĺbĘlü M no| lb lunb
Affi
'Íĺ
Útn
'ptdldŤ*alhffi
13
rrc'ođE
M
b
dffiffi-tudti@tuffi
fuń*hffiďň
ďffiffi-
tu-ąlthffi
Nüňfułb
tu.8#Bbtu
tlúerńhlńtd Drí
ffiŕřmdď
. ltť. lrř r ł 
'c..
'hmfrrF$*@I
FBtaÉ|5d| E(.Indtr
- aLt. dtanoaiTt
-Éŕ!*
. nał..fu cÜřD:.ffir*ła
lbalatłđilb.
>3sr
F€rffi
<Sm
PEŤńa
.ffilún
ťatí|*'
. tĺoĘ .fuli-lŮrk
?'đamä-
drffiTy
.8iĺ bqbila-
.uÍ*ĺ!'úüať
ń
lňfrülłlt'
r 0..d fil.ńca
í0(Íc0)l
PBra#.(lđ6a}
ńallaffír'
rFtlrS*
lrĘńs|
!.đłďt|PEx4ŕ.
líŇt|Édoůtí
.ňníiłłý..l llct
lF'äĐńdw
.ł{adlňďrłÍ
mťfr.ÚĎlřĺ'b
loůd.aa..
błlat
FEl1aĺra
.BrlÉ.
.ĺłffi{-.a
L{únď
l"*,.-.*'",,'
F*tłriril!ĺh|at
.c.łeĽr 1qÖ ,rr '.W
hntltiat
ll,ĺl' j li!ĺĺ ]ti il'l,,]liii ul[ ' ŕ"] i )!]lilI lllłli
14
ĺ-
ĺ-
I
I
ĺl
{,i
I
I
oulcqn (> 9896 suív|'ŕal)
drbĺBnl lĺ€ámBnü ĺblbľ' up
adlułrnt ďemothoĺapy
(PEB x 2 cĺdeg)
0r
ilĺvÔlll'nce
ffih$m0'Hloh rlrk"
(veroJlaľlmdon}
Onlybľvory mtlctd cosoo
(oo. lí&gmotfunpyor
eurvdĺĺno drdlnod by hr
paücnt)l noí'/c tFlĺlľ
RPLND
0r
aqwantđomoüBÍapy
(PEB x 2 cydeo)
oytbs)
Isuľeillance
'l.ovňlť
(no varallar lľalon)
|]]n.l'iln|ll l'1 |i 1,'I'lĺ:iilill 'i'.! ^|']1.l ! l1i!t]ĺ'|l,'j!]ĺ; i' l,l
r Folloťv up
oŕ
rPEBx2cycles
oŕ
rPEx2cvolea
).Pathologioalgtage lll'/B
łr Pathologlcal
shgo I
8uľelllance (lndepondont ď r'asculal
lnva.lon)
Bftlúcgyľ
aotive troaÍnénĺ blopŚy
or riong apańngFRPLND
. Rooirs3lon t FuľlheÍíollr$, up
rNC Đ Noĺvogpańno-RPLND
FEB x 3 oycłes (ol PE x 4 oyclos)
oŕ
NoÍvo wańng-RPLND
Đ. P0' mäľkEr
řomalnB eBbrtpgy í'
rolloÍt, up only q 6 wéots
r PD, and
marker o
PEB x 3 ovolcs (oÍ PE x 4 rylo.l' ln
oarc oÍ iosldual tumouí(> 1 cm):
ĺcgarüon
ł
Řoggotlon and Íollo^, up. RieBual'tumor )
(r I cm)
0hemothcľapy
r 8teńdárdi PEB x 3 cydol
r optlon: PE x 4 oydoô
.CR ż FÓllo^t up
r .' '_l ĺĺĺĺüilĺ ĺl 1tr,,l''1ĺl|"1n1' ĺll]l l l']illł ! lĺ0|liill,,lĺ!i ;l ĺ''l. '!' '" '
li
i.t
ll
fi
i_r
L1
Irll
15
ot
) 8,rTÓ.'úlaŕ
ł sałrňńt/
.)Mr
dídB)
. <l2ĺ
.r*ba
) toko{tĺ
lĐdpqŮt
.}t2ĺ
atm!
ur*raaŃrłr'übď
l!ĺE-
'ťte'brloĽlüö
' 
&Qqłlzl
.l*l.oĺÍűđtb
sĺ
.Ú.Ďtsm
. ĺ!'ü. rmĺFÍ<ĺoĺ
.ĺnffi
.ĺ,*fu>ĺ0ĺ
. R?. üłraLl'Éa J oĺ'rrtqÚlt
' 
ńltrĘ
' 
f.kł
rnU ł 8ałr*'ldŰ.lú
tk
raŇ|*tmÍ
) ŕr-ę
' 
Fü?
' 
F.bł
-'l ^ -.
aĺ
'ď-Eűł''lmrF
'*aitÍłl-bffiHďl*dnÉlreťĆdĘh'är&''!ff ĺ+ütlł
ll', : łilĺlt.l,l, li',I''lĺIiiL'lĺ'ĺl;,ł,'l 1,i1''r 1,r1, l i.;l i,r{"] ]| ' ĺ lĺĺ1J]]|l ,]ľĺí li: ł,ĺ, llĺr ]!ĺ
b Dđenrĺneťon of letá .tbob: uľee ánd oĺoctÍoly{.s, fartlng ńolestcÍol (HDl. LDL), ülgĺyccrldcG, fastĺn glucor., FsH, ul,
o Pollclea vary among oouilílo8 end hoopitáb and thoío ir no defrnillvo ovidonco'
cT l.łx unül oR wlth oĺ !,l,iÜloul 
'Jł!3Íy' 
ülan
accordlno b ďr.Et x.Ía, olán
cT ebdomsn/pelvlg
3x3xChcat X-rav
3x6xxanvmerkoÍE'
ĺx1x2x;T abdomon/oolvlE
3x;ne8t )Gr8v
xam/maÍkcr8'
jT abdomôn/D6lvl3
2x2x,roSt x-rav
2x3x4x:xam/mad(org"
(1$ť1xĺxu2xCTaMomen
íĺx)ť1xĺx2x2x2xOhest X-rav
í1xlľD(2x2x3x4xExam/marlĺerg'
lT abdomen
ĺx1x)hôst x.ráV
ĺxixänvfiařl(eÍs'
HCO,
'/' il''}Yrl/ 
'ijl,)' 
ŕ,,]' l ) ll]ľl!.)i:ir
1 6
ffi ü'ĺaq')
' sa{.đít/
.)
)
' 
ř.bĘqlt
hĺďFrF*
. >ĺ2r
.Ľffi!
rhr$lĺň.
[łlí-lrüŕ
EÍĺ-id
'.álllffi,LtÉ,ľ!đĎ
+ &Ęq+[r
.l*M-dđÉ.l
.na,DfltW
.mtĘLťĺt lt<lot
.m,tri
.n!.*tm''lĺ
.nĺ.'ŮÜrírqb
ł ŕüt?LňŮĺfu ł ŕrĘł
.iĺI2 ł 8a.'r.ńdlĘ!alť'u
-łrp
l*o'*,
J FłliraÉĺ
a Fü?
ł ŕűo
t fuł|ł
Bt
lď Eilńá'-Lfü Érd!ĺŮdirya
'ď-EtlFĺÉ
l:,'ť.it
..a 
^
,,.r. ,ł .']
,l\'
mĺcrollthlaslsIi
L,
ll
it
17
TnŮnr*
oÍÚ{daclctly
oa
Ítďď'aĺ?ľ
8ďEtÜŮr&ílĺ'aaü'aaT{üąLtBlop.y
8ďExmlírdoírnoAe.frĄ
lutaa!0nrr
8ďEnt'hŮílnÖ
ffity
ELbltl1Ül
cł't?lilřJfrĺ'
^Ü!ĺłťoffi.ĺ.
T.ĺĺrJ|a
liloÍoü*
Follow-up schemo foľ patlont9 with
TM wlthout a concomltant
testiculař tumour.
lnt J Androl. 2009 Aug;32(4):279-87
-ł
I
I
B
I
I
I
mqt,oo
roo0o
0,oo
+
tilltlrlb
clin Gancer Res 2009;í5(í0) May í5' 2009
18
Phase ll trial of sunitinib in patients with relapsed
or refractory germ cell tumoĺs
Darren R. Feldman & Stefan Turkula &
Mlchelle S, Ginsbsrg & Nlcole lshill & Suiata Patll &
Maryann Carousso & George J, Bosl & Robert J. Motzer
lnve3t Now Drugs (2o1or28':52#28
alI patients progressive diséase within three cycles of sunitinib
some marker decline during the active treatment period with
subsequent marker rise during the twoo-week off peroid ---ł dosing
scedule of sunitinib 37.5 mg / day cintuinously
in general sunitinib well tolerated ( no grade 4 toxiclty )
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Metastatic castration-resistant
prostate cancer (mCRPC)
Boštjan Šeruga, MD
Sector of Medical Oncology
lnstitute of Oncology Ljubljana
November 12, 2010; Ljubljana
Outline
r How "rare" is CRPC?
r Biology of CRPC and mechanisms of reslstance
to standard therapies
r Current drug development in CRPC
1
lncidence and mortality rates for
prostate cancer (World)
Most frequent cancers in males Prostate cancer
NoĹHodokin
Lip' olôl
BÍain' nercus
Olhor
I lnodsnce
l lýofulity
AsR (lfl) Íals peí 100'000
GLOBOCAN,2008
RARE
lncidence and mortality rates for
prostate cancer (Slovenia)
cancers in males
Mońality I Prostate
I Lung
Colorectum
I Stomach
t BladdeÍ
I Kidney
I Molanoma oĺskin
I Pancreas
l Lip' oÍal cďity
ohoÍ
B19 (2ô.396).........-
44 (l 19{)
155
56
82
121
208
-4lg 
(1J.4%)
. 367 men died of prostate cancer in Slovenia in 2008
. ASR (W): í9/{00'000
. ln Europe Denmark, Estonĺa' Lithuania' Latvia and
Sweden have higher mortality ratesAsR0v)ratop0í 100,000
Lrp,oral
NotoHodlhn
Brain,
llmiffio
l MoíalilY
GLOBOCAN,2008
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Guľtont definition of GRPG
r castľation_resistant prostate cancer
(GRPG):
. Castrate levels of testosterone (< 0.50 nglmL, 1.7
nmo!/L)
. Evidence of cancer progression (PSA or imaging)
r lt is not Hormone-resistant prostate cancer
(HRPC)!
What are the goals of any
cancer treatment?
. To allow the patient to !ive longer
and/or
. To allow the patient to live better
3
Pivotal phase lll clinical trials with
Mitoxantrone in mGRPG
Mitoxantrone allowed patients with mGRPC
to live better
t Quality
of Life
PrednisoneMitoxantrone
+ Prednisone
Kantoff/í999
(JCO)
t Quality
of LifePrednisone
Mitoxantrone
+ Prednisone
Tannock/í996
(Jco)
ResultsGontrol
arm
Experimental
aľm
Authorľear
(Journal)
Pivotal phase III clinical trials with
Docetaxe/ in mCRPC
Docetaxel allowed patients with mCRPC
to live longer and better
t Survival
Mitoxantrone
+Prednisone
Docetaxel
+Estramustine
Petrylak 2004
(NEJM)
t Survival
l Quality
of Life
Mitoxantrone
+Prednisone
Docetaxel
+Prednisone
Tannock 2004
(NEJM)
ResultsGontrol
arm
Experimental
arm
Author/Year
(Journal)
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Outcome of patients with mGRPG
25.8
Asymptomatic/
Minimally symp
IMPACT (Provenge@)
Kantoff,2010
18.9
Symptomatic/
Minimally symp.
TAX327 (Docetaxel)
Tannock,2004
10.8SymptomaticNCIC (Mitoxantrone)
Tannock, l 996
Median OS
(mo)
Patient
populationRCT (Drug)
How many patients with mCRPC
do we treat with docetaxel?
Are our patients undertľeated?
Courtesy of mag. Petra Tavčar & Samo Rožman
- 370 men die of prostate cancer in Slovenia annually
60 (16,2o/o)2010 (until 09/20í0)
43 (11,60/o)2009
17 (4,60/o)2008
16 (4,3o/o)2007
No. of patients treated with
docetaxel
Year
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Mechanisms of drug resistance
in CRPC
Seruga, Ocana & Tannock, Nat Clin Pract Oncol, 2010
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Mechanisms of drug resistance
in CRPG
Seruga, Ocana & Tannock, Nat Clin Pract Oncol, 2010
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Opportunities for
drug development in mCRPG
r Drug "X" re,-Docetaxel
r Drug "X" and Docetaxel
r Drug "X" E!-Docetaxel
New chemotheľapeutic
agents in GRPG
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Molecular concept model of
pľostate cancer progression
With prog ression proliferative activity lncreases
Tomlins, Nat Genet, 2007
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Mechanisms of resistance
to taxanes
Seruga, Ocana & Tannock, Nat Clin Pract Oncol, 2010
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Evading resistance to taxanes
RGTs evaluating
hemotherapeutic agents in mGRPG
NegativePFS, OSN=950
Satraplatin+P
Placebo+P,2009Stern
SPARC
TROPIC
Sartor,20'10
Positiveos
N=755
Cabazitaxel+P
Mitoxantrone+P
Estramustine+D+P
D+PMachielis, 2008
NegativePSA resp.
N=150
Expeľimental a
Gontrol a.
RGTs ResultsPrimary
endpoint
Drug X + Docetaxel
Drug X post-Docetaxel
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Toxic deaths due to infections and diarrhea!
2010 OenitourrnarV Cance rs Synrposium
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Targeting AR-associated
signalling in GRPG
11
Moleculaľ determinants of resistance to antianđrogen
therapy
Chĺrlie D Chen|'5's, Derek S Welsbie3,5,s, chris Trĺnl'a, Surrg He Bueléś, Rĺn<ty Chenl, Robeľt Vessella7,
Michĺrel G Roserlfeld{ń & chĺrles L sowyeľsl_5
. AR over-expression causes hormone refractory progression
. AR expression is necessary for hormone-sensitive to
hormone-refractory prog ression
. AR-mediated progression occurs by a ligand-dependent
mechanism
. Increased AR expression converts antagonists to agonists
ĺlaĺlner.
meoĺcüle 2004
AR is oveľ-expressed in cRPc
Androgen Receptor Expression
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AR-associated sig nall i ng
in GRPG
Seruga, ocana & TannocĘ Nat Clin Praď oncol, 2010
Abiraterone acetate
rEĘ
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Targeti n g AR-associated
signalling in GRPG
Seruga, ocana & TannocĘ Nat Clin Pract oncol, 2010
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Abiraterone acetate
MDV3lOO
Blcalutamlde
progestlns
PÍollÍeratlon
ntlapoptotlc eff€ctab Mutatéd AR
f Acüvatlon oÍAR by RTK
De novo
@6
e e
Upragulatedc nuclear
coađlvators
Targeti ng AR-associated
signalling in GRPG
Seruga, ocana & Tannock, Nat Clin Praď oncol, 2010
RCTs evaluating agents targeting
AR-associated signalling in mCRPC
OS: Overall Survival; P: Prednisone
AFFIRM OSN=1,170
MDV3lOO
Placebo
Recruiting
Abiraterone+P
Placebo+P
cou-AA-301
De Bono, 2010
Positiveos
N=1 ,1 85
cou-AA-302 osN=1,000
Abiraterone+P
Placebo+P
Recruitment
complete
Phase lll
RCT
ResultsPrimary
endpoint
Expeľimental a'
Control a.
Drug X pre-docetaxel
Drug X post-docetaxel
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Abiraterone acetate:
lnhibitor of Androgen Synthesis
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Experience with abiraterone in
early phase clinical trials
Pre-docetaxel Post-docetaxel
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Milan 2010 COU-AA-3O1 Baseline Demographics
agc, yrers 69.0
(42.95) (3e.e0)
Race
VVhlte
Black
ABlan
ECOG-PS 2
slgnlÍlcsnt paln p'esént
2 Prlor chemotheraples
R8dlographlc PÍogresslon
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10.?%
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70,101o
02.7%s
3.8%
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28.3alo
69.6%
TotalPlacebo
(n = 398) (n = 119s)
AA
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Milan 2010
cou-AA-30í : Abiraterone Acetate
lmproves Overall Survival in mCRPC
1I69í80206352398Placebo
02520447563í724757AA
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2 Prior Chemo OS:
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ĺ Prior chemo os
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Milan 2010 COU-AA-301: AEs of Special lnterest
Fluld r€tentlon
Hypokalaemla
LFT ebnoľmelltlca
}lypeÍtenslon
cardlac dlśorder8
30.6%
17.1o/o
10.4o/o
g.7olo
í8.3%
2,30h
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1.3%
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2!2.3oÄ
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All Grades Grades 3/4
(n = 791)
AA
Grades 3/4All Gredes
LFl liveľ function test
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Targeti ng ang iogenesls
VEG F-targeted strateg ies
. mAbs targeting VEGF-A (a)
. mAbs or small molecules
VEGF receptors
. Aptamers that bind the
heparin-bind ing domain
VEGFl 65 (pegaptanib) (e)
. Chimeric soluble receptors
such as VEGFłrap
1š.*
vacm
\(t*"
(domain 2 of VEGFR-1 and domain 3 of VEGFR-2 fused
to a Fc fragment of an antibody) (d)
i. i
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RGTs evaluating
antiangiogenic agents in CRPC
SUN 1120 Sunitinib+ 
P
Placebo+P
Discontinuedos
N=819
Lenalidomide+D+P
Placebo+D+PMAINSAIL
Recruitingos
N=1 ,015
Aflibercept+D+P
Placebo+D+P
VENICE RecruitmentComplete
os
N=1,200
,2010Kel
CALGB 90401 os
N=1,020
Bevacizumab+D+P
Placebo+D+P
Negative
Phase lll
RCT
Experimental a.
Gontrol a.
ResultsPľimary
endpoint
Drug X + Docetaxel
Drug X post-Docetaxel
Targeting bone micľoenviľonment
19
Bone-epithelial interaction central to
prostate cancer prog ression
Osteoblastic Bone Disease
Bone microenvironment
Endothelin
{9q t/
6(E
r cells
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Targeting bone microenvironment
oo
o
oo
cells
2. Src inhibitor
í. Endothelin A receptor
3. Bone-seeking
radiopharmaceuticals
RCTs evaluating agents targeting
bone microenvironment
cÁ.180-227 RecruitingosN=1,380
Srcpą5ąfini!+p+P
Placebo+D+P
Zibotentan+D+P
Placebo+D+P
Enthuse M1c RecruitingosN=1,044
ER
swoc so421 OS, PFSN=930
ERAtrasentan+D+P
p1ą6g5g+p+ P
Recruitment
complete
Enthuse M1 RecruitmentcomN=848
osERZibotentan
Placebo
Atrasentan
Placebo
Carducci, 2007 NegativeTTP
N=809
ER
Experimentala.
Controla.
Phase lll
RCT
ResultsPľimary
endTarget
Drug X pre-Docetaxel
Drug X + Docetaxel
2L
RecruitingosN=750
Bone
matrix
Alpharadin
Placebo
ALSYMPCA
Recruitingos
N=480
Bone
matrix
D+P or ](AVE- Sr+A
D+P or KAVEMD Anderson
ResultsPrimaryendpointTaľget
Expeľimental a.
Controla.
Phase lll
RCT
RGTs evaluating agents targeting
bone microenvironment (cont.)
Alpharadin: Radium-223 (oładiation)
Sr: Strontium-89 (B-radiation)
Drug X + Docetaxel
DrLrg X post-Docetaxel
Osteoclasts present irrespective
of radiology
Osteolysis
Osteoblastosis
\
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Zoledronic acid in mGRPC
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SRE Phase Ill study in mGRPG
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New immunoherapeutic
strategies in GRPG
Whole-Gell Prostate Gancer
Vaccine (GVAX@)
. GVAX prostate cancer vaccine is a GM-CSF secreting
whole-cell vaccine composed of prostate cancer cell
lines (PC-3 and LN-CaP) genetically modified to secrete
GM-CSF
. GM-CSF (sargramostim) can expand and activate APCs
. Whole-cell vaccines, unlike peptide vaccines, express
multiple tumor antigens and are capable of eliciting a
broad immune response; especially important if the
"best" antigen target is unknown
25
AnAutoIogous Gellular immunotheľapy
S i pu leucel-T (Provenge@)
week 0 2 4
RGTs evaluating
new immunotherapies
Negative
N=408
osMultiple
ens
GVAX@+D+P
D+PVITAL.z
Positiveos
N=521
PAPProvenge@
Placebo
IMPACT
Kantoff,2010
NegativeN=626
osMultiple
Antigens
GVAX@
D+P
VITAL-1
ResultsPľimary
endpoint
TargetExperimental a.
Gontrol a.
Phase lll
RCT
Drug X pre-Docetaxel
Drug X + Docetaxel
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Phase lll IMPACT Trial
Primary endpoint:
Secondary endpoint:
Overall Survival
Time to Objective Disease Progression
Asylnptolratic or
Minimally
Syľnptomatic
Metastatic
Castrate
Resistant
Prostate Całrcer
(N=512,)
P
R
o
G
R
E
S
S
I
o
N
S
U
R
I
A
L
Sipuleircel-T
O2weeksx3
Placebo
Q2weeksx3
Treated at
Physrcian
clrscrctron
Treated at
Phys ician
dlScíetion
and/or Salvage
Protocol
- 
Placebo (n = 171)
Median Survival: 21.7 Mos.
KantoĘ NEJM' 2010
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Negative RCTs
The cemetery of dead drugs in
struggle against CRPC
r lnactive drugs?
r lnappropriate target?
r Lack of appropriate
patient selection?
28
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Tanja Cufer, MD, PhD
University Clinic Golnik, Slovenia
Medical Faculty, University of Ljubljana, Slovenia
Neuroendocrine tumors
Lung NET
lncidence of NET is lncreasing
1.40
1.20
1.00
NET Site
oo
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Lung
Colon
Small intestine
Rectum
Pancreas
0.60
0.40
0.20
0
Year
SEER = Surveillance, Epidemiology, and End Results;
Appřoximate s_fold increase between 1975 and 2004
Approximate 7-fold increase also evident in Norwegian registry
Yao J, Hassan M, Phan A, el al. J Clin Oncol.200A:26:3063-3072.
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NET Vary by Primary Tumor Site
r Generally characterized by their ability to produce peptides that
may lead to associated syndromes (functionalvs nonfunctional)
r Historically classified based on
embryonic origin
n Foregut tumors
n Midgut tumors
n Hindgut tumors
r Today, primary tumor location is
recommended for NET classification
Midout
. Appondix
. lleum
. Cacum
. Asc€nding coloĄ
Hindout
. Distal large bowe
. Rectum
1 . Modlin lM, el al. Lancet. 2oo1i9:61-72.2. Modlin lM, el al. Gastrcenterclogy. 2005;128:1717-1751
Foroout
. Thymus
. Esophagus
. Lung
. Stomach
. Pancrcas
. Duodônum
Diversity of NET Has lmpacted Nomenclature
r Although some commonalities exist, NET include a diverse family of
malignancies
r Range of behaviors/aggressiveness
n Poorly vs. well differentiated
n Tumor grade (G1, G2, G3)
n Benign vs. malignant
r Extent of disease
n Local vs. distant metastases
r Location of primary tumors
n Lung, colon, small intestine, rectum, pancreas, etc
r Symptomatic vs. asymptomatic
n Symptoms due to hormonal syndromes vs tumor mass
'l' Klimstra Ds, ot al. Ám J suÍg Paŕhol 2010:34(3):300-3'13. 2' Modlin lM, Gasŕŕoenŕerc/ogy. 2005i128:1717-1751. 3' Modlin lM'
et al' Ĺanc€t onco/' 2008;9(1):61-72.
Correlation of Primary Tumor Site with
Survival
Advanced dlsease
r Known prognostic factors include:
n Location of primary tumor
n Extent of dĺsease
n Tumor stage
n Degree of differentiation/
proliferative index (Pl)
n Tumor grade
n Patient age
n Performance status 122436 72 84 96 108120
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Roctum
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65% of patients with advanced NET will not be alive in 5 years I
Yao ét al' J clin oncoL
New Treatment Modalities
PROMID: Octreotide LAR in advanced Midgut tumours
1 .0
Octreotide LAR vs placebo P = 0.000072
HR = 0.34 [95% Cl: 0.20-0.591
_ octreotide lÁR (n = 42)
Median 14.3 months
.9ooo
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- Placebo (n = 43)
Median 6.0 months
.25
Based on conservative ITT analysis
0 6'l2 1824 303ô4248 5460667278
Tlme (months)
Rinke A, Bańh P, Wod M, ot al. J clin oncol.2009;27:4656-4663.
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Pulmonary NET Classlfication
r Low grade
nTypical carcinoid
r lntermediate grade
nAtypical carcinoid
r High grade
n Large cell neuroendocrine carcinoma (LNEC)
n Small cell carcinoma (SCLC)
Lung NET Frequency
Atypical Carcinoid 0.1 -0.2%
Carcinoid 0.1-2.00/o
EC 3.0%
scLc 15-20.0%
Non-NE
Carcinomas
75-80.0%
.I
Lung NET: Clinical Features: Japanese
Registry
Asamura H et al: J Clin Oncol 24: 70,2006
scLcLCNTCACTC
Lung NET Pathologic Differential
* Chromogranin A, synaptophysĺn
9CLOLCNECAC
I
Typical and Atypical Carclnoid Diagnostic
Criteria
r Typical Carcinoid
u Less than 2 mitoses per 10 HPF (2 mm2) and no foci
of necrosis
n Centrally located tumors, endobronchial grovuth
r Atypical Carcinoid
a2-10 mitoses per 10 HPF (2 mm2)
OR
n Foci of necrosis
n Peripheral lessions
Travis WD, st al: Am J Surg Pathol 22: 93444, 1988
Typlca! Carcinold
Atypical Carcinoid
Pulmonary NET
Survlval rates of surgically resected dlsease
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P <.0001
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Lcľ'lEc (n r 141)
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\tar8
5 %-yr Survival
TC:87%
AC:56%
LCNEC:27%
SCLC:9%
Asamura H at al: J Clin Oncol24:70,2006
Typical and Atypical Carcinoid
r Most patients with TC are diagnosed with limited disease
n Conventional surgery represents a standard treatment, with S-year
survival oÍ 92%-100%
r AC patients have a significantly worse prognosis with
reduced S-year survival of 610Á-880/o
n Most of the patients are diagnosed in advanced stage
n Conventional chemotherapy has limited efficacy for patients with
advanced NET
r Octreotide LAR, historically used for symptom control in Gl-
NET, prolongs time to progression and improves QoL
r New agents, like bevacizumab, sunitinib, everolimus might
be beneficial in pts with in low -, intermediate grade NET
tumors
Rationale for Combining Everolimus and Octreotide
LAR
r NET have been linked to genetic
alterations that activate the
mTOR pathway
r Everolimus inhibits mTOR
r Octreotide downregulates IGF-1,
an upstream activator of the
P|3I(AKT/mTOR pathway
r Everolimus + octreotide LAR has
shown activity in a phase ll trial
r mTOR is a central regulator of
growth, proliferation, metabolism
and angiogenesis
RADIANT -2: Study Design
Phase lll Randomized, Double-Blind, Placebo-Controlled, Multi-Center
Trial
Patients with
advanced well,-
moderately
differentiated NET
with a history of
carcinoid
syndrome,
N=429
Lung N= 40
ĺ:í
Treatment
until
disease
progression
Grossover
Placebo + octreotlde LAR
30 mg/28 days
n =2ĺ3
Multi-phasic CT or MRI performed eveyl2 weeks
Primary endpoint:
. PFS (RECIST)
Secondary endpoints:
.OS
. Safety and tolerability
cllnl@ltÍi8ls'gov: NcTo04í 206í
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RADIANT 2: PFS by Central Review
100 Kaplan-Meier median PFS
Everolimus + Octreotide LAR:
Placebo + Octreotide LAR:
o
(t)
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16.4 months
1'ĺ .3 months
Hazałd ratio = 0.77; 95% cl 10.59 -1.00l
P-value = 0.026
Total events = 223
o Censoring times
*E+O(n/N=1031216)
P+O(n/N=1201213)
0
o246
No. of patients still at risk
8 ',to 12 14 16 18 22 24 26 28 30 32 34 36 38
E+O
P+O
Time (months)
216 202 167 129 1
213 202 155 117 1
20 'lo2 81 69 63 5ô 50 42 33 22
06 a4 72 65 57 50 42 35 24 18
17
11
11 4 1 1 0
93 I 0 0
Pavel M etal,; ESMO 2010
RADIANT 2: Treatment Related Adverse Events
*Relatod toxicitios groupôd for calculations
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Large Cell NE Carcinoma Diagnostlc
Criterla
r NE Morphology:
Organoid nesting,
trabecular, palisading,
rosette-like patterns
r lncreased Mitoses (11
or more oer't0 HPE or
mm2)
r NE differentiation by
immunohistochemistry
or EM
LCNEC: NCC Research lnstitute, Tokyo
t 87 cases (3,1o/o resected lung cancers)
r Sex: 77M (89%); Mean age 68 yr (37-82)
r Smoking: 98%; No paraneoplastic syndromes
r S-yr survival - overall 57o/o
n Stage l: 67%; ll:75o/oi lll: 45o/oi IV: 0%
n Stage I LCNEC: 670/o; PD NSCLEC: 88%; LCC: 92o/o
(P=o'oo3)
n No difference between Stage I SCLC and LCNEC
Takei H et al: J Thorac Cardiovasc Surg 24: 285,2002
I'
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LCNEC: Chemotherapy
Adjuvant Setting
(Platinum/etoposide vs Gemcitabine/taxanes)
Metastatic Setting
(Platinum/etoposid6 vs Gsmcitabine/taxanos)
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Rossi G eta al: J clĺn oncol2s:8774'2005
LCNEC: Chemotherapy
r lyoda A: JTCVS 138:446,2009
n 79 LCNEC; 36 recurred; Pts receiving platinum based chemo -
significantly better DF survival (p>0,001 )
r Saji H et al: Anticancer Drugs 21: 89-93, 2010
n 45 LCNEN pts; 23 (41%) perioperative chemotherapy (mostly
platinum based) - better survival (p=0,04)
r Igawa S et al: Lung Ca 68: 438-45,2010
n 14 HG NE carcinoma c/w LCNEN; clinical etficacy of chemo
comparable to ED-SCLC
SCLC Pathology Criteria
Couftesy of I Kern
I
I
SCLC Radiologic Criterla
Bulky, widespľead mediastinal
disease
Courtesy of I Pozek
I
SCLC - Progress in Therapeutic Outcome
- 
Radiotherapy
*'' Surgery - 
chT+ Pcl
- 
ChT+ RT
- 
chT
20o/o
í5%
10%
'l 2
of J Jassem
3 years
ť"ĺ"'
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Cisplatln / Etoposlde Versus CEV
> Cisplatin/Etoposide is superior to CEV
> Subset analyses revealed Cisplatin/etoposid superiority only in LD
Sundstrom S et al. J Clin Onco! 2002i 20(24): 4665-4672.
Unmet Medical Needs in SCLC
r Topotecan improves survival and symptom control
vs. BSC in second line therapy, thus representing a
standard SL therapy
r New platinuń based combinations
(i ri n otecan/p lati n u m, pemetrexed/carbo) fai led to
show superiority to cisplatinum/etoposide schema
r Amrubicin is a new agent of promising efflcacy in
relapsed SCLC, phase3 trial comparing amrubicin vs
topotecan is underway
r So far, numerous targeted agents failed in SCLC
> To improve treatment results molecular predictor of
response to either ChT or targeted agents need to be
explored more profoundly in a near future (ERCC1,
topo2, VEGF, ...)
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Pulmonary NET Treatment
Pulmonary NET - Progress in Therapeutic Outcome
EsMo quidolinos. Ann onc.l 2o1oi 21 :Ý220-222i NccN guidrlinrs
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ln Summary
r Pulmonary NET include a wide spectrum of tumors, from low-grade
TC, intermediate-grade AC to high-grade LCNEC and SCLC.
r Most of pulmonary NET express neuroendocrine markers, while
paraneoplastic symptoms are quite rare.
r Nowadays, a proper anatomical staging (according to UICCT edition)
and sophisticated pathomolecular tumor classification are of upmost
importance for effective therapy.
r Surgery, irradiation and chemotherapy still represent the mainstay of
therapy, However, new treatment approaches based on better
molecular markers identification and new targeted therapies are
supposed to further improve survival rates and Qol of patĺents.
Multidisciplinary teams should take care of pulmonary NET
patients!
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Lymphomas in patients with
HIV infection
Clinical cases
Doc.dr' Barbara Jezeršek Novakovió,dr.med
Gregorič Brigita, Matej Horvat, Tanja Mesti
Glinical case 1
. M, 37 years old
. HIV-1+ patient; otherwise healthy and did not take any
medications
. Presenting history:
Upper abdominal paln and obstructive icterus since April
1 998
Despite the ERCP with an insertion of a stent into the
dilatated d.choledochus there was no improvement
. Physical examination: PS WHO) 3, icterus, no enlarged
lymph nodes, ascites
1
INITIAL INVESTIGATIONS:
. Leu 9,19; Ery 5,5; Hb 164; Ht 0,46; MCV 83,7;Plt 619;
neutro 77o/oi lymph 1970, mono3%o,eoz0o/o, baso 0%;
biochem.- pathologic liver tests (bilirubin 349; AP 12,30i
gamaGT 32,48; AST 6,81; ALT 4,49); creatinine 137;
urea 15,4; uric acid 849; LDH 25,58; CRP 6
. HIV-1 RNA (PCR) 8902 copies/ml, CD-4 count 114lmm3
. CXR: minimal pleural effusion in right interlobar fissure
. XR of paranasal sinuses: normal
INITIAL I NVESTIGATIONS:
. CT of abdomen: extensive ascitic fluid (3-4 L), infiltration
of peritoneum, atrofic left hepatic lobe probably due to
the occlusion of the left branch of venae portae and left
hepatic vein. Larger tumor mass in the left hepatic lobe
and in porta hepatis, marked dilatation of intrahepatic
ducts, stent in d.choledochus
. CT of thorax showed minimal pleural fluid left and hiatal
hernia, but was othenľise normal
2
OTHER INVESTIGATIONS:
. Ascites - cýology: diffuse large B cell lymphoma
(CD10+, FMCT+, CD52+, CD38+, MIB-1 50%)
. Biopsy of bone marrow: no lymphoma infiltrates
Conclusion: diffuse large B-cell lymphoma,
cytological diagnosis, stage IV.A.E.
lnvolved regions: liver (left lobe), peritoneum, ? pleura
left, lPl 4.
. Diagnosis of lymphoma and HIV infection was made
simultaneously
TREATMENT:
. Treatment in April 2008: methylprednisolone in
increasing dosages (16 mg+125 mg) from the first day
of hospitalization; an attempt to treat the patient with
modified CVP on the day 4 (50o/o dosages)
. However, the patient's condition was irreversible, hĺs
hepatic and liver function progressively deteriorated
(hepatorenal syndrome) during hospitalization and the
patient died on day 6.
3
Glinical case 2
O M, 54 years old
HlV-1+ patient, othenľise healthy and did not take any
medications
Presenting history:
Swelling in the right parotid region for the last 2 months
growing rapidly to a mass with 15 cm in diameter
(spreading down to neck, behind the ear and up to the
temple), headache, troubles with opening of his mouth,
weight loss of 4 kg, no constitutional (B) symptoms
Physical examination: PS (WHO) 1, large mass in the
right parotid region (15 cm), other lymph nodes not
enlarged, white coating of tongue
a
a
a
INITIAL INVESTIGATIONS :
. Leu 5,9; Ery 4,95; Hb 158; Ht 0,433; MCV 87; Plt 365;
neutro 69%; lymph 22o/o, mono 8o/o, aoz 1o/o, baso 0o/o;
biochem'- gamaGT 1,1, s-proteins 100, othenľise
normal biochemistry (LDH 3,28)
. HIV-1 RNA (PCR) 250.000 copies/ml, CD-4 count
231lmm3
. CXR: normal
. XR of paranasal sinuses: normal
. ORL examination: protrusion of pharyngealwall on the
right side
. US of abdomen: normal
4
OTHER INVESTIGATIONS:
. Cýology of the tumor under the right ear:
morpholog ical ly and imm u nocýochem ical ly B u rkitt's
lymphoma
. Biopsy of bone marrow: no lymphoma infiltrates,
moderate to marked siderosis
Conclusion: Burkitt's lymphoma, cytological diagnosis,
stage l.A.X, risk group (Murphy) 2.
lnvolved regions: lymph nodes in the ľight parotid
region extending down to the right side of the neck.
. Diagnosis of HIV infection was made prior to the
diagnosis of lymphoma
TREATMENT:
. Treatment from May 1998:
Cytoreduction (5 days) with methylprednisolone
and cyclophosphamide according to BFM protocol
. First A cycle (MD MTX, lfosfamide, VP-16, Ara-C and
dexamethasone) and prophylactic intrathecal
chemotherapy from day 5 onwards
Compĺication: 9 days after the first cycle the patient
developed febrile neutropenia and stomatitis (Leu 0,42;
Hb107; Plt 66) and needed to be hospitalized
. Clinically CR after the first cycle, US (neck) showed
lymph node in parotid region (14X7mm) and on the right
side of neck (15x6 mm)
j'
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TREATMENT:
. Second B cycle (MD MTX, Cyclophosphamide,
Adriamycin, Vincristine) and prophylactic intrathecal
chemotherapy in June 1998
Complication: 6 days after the second cycle the patient
had to be hospitalized because of febrile episode and
stomatitis (Leu 1,9; neutro 75o/o, Hb 85, Plt 146). The third and the last fourth B cycle with prophylactic
intrathecal chemotherapy were applied in July 1998
Complication: stomatitis after third and fourth cycle. No prophylactic antimicrobial therapy during
chemotherapy. Prophylactic G-CSF (3 -5 days) after every
chemotherapy cycle
FOLLOW UP:
. The control US of neck in September 1998 showed
reactive lymph nodes on the right side of neck (0,7 cm)
. !n September 1998 the patient refused to take anti-
retroviral medications adviced by the infectologist and
would not start them until 1999
. The patient was followed by regular medical
examinations for the first 5 years, no relapse of
lymphoma had been confirmed (since July 1998)
6
Retrospective cllnical trial
. lnclusion criteria:
diagnosis of malignant lymphoma
diagnosis of HIV infectlon or AIDS
. Patients treated at the lnstitute of
Oncology Ljubljana
. Period 1998-2009
. 9 consecutive patients
Patients
. 9 male patients, 0 female patients
. Mean age at the discovery of lymphoma
48,0 years (range 24,0-59,5)
. Mean age at the discovery of HIV infection
47,2 years (range 20,0-59,5)
. 4 patients diagnosed with HIV infection at
the time of diagnosis of lymphoma
. 5 patients diagnosed with HIV infection
prior to the diagnosis of lymphoma
7
Patients
. I diagnosed with NHL:
5 diffuse large B cell lymphoma (DLCBL)
2 Burkitt's lymphoma
1 plasmoblastic Iymphoma
. 1 diagnosed with HL:
mixed cell type
Type of lymphoma
5
4
lTYpeof lyńphoma
2
1
0
OICBL Buíłltl lymphom. Pl.!ńoblôstic lyńphoma Hod8łln lyńphomó
I
Patients
. Clinical stage of lymphoma:
Stage l: 3
Stage ll: 3
Stage lll: 1
Stage IV: 2
Clinicalstage
3,5
3
2,5
2
1,5
I Clinicalstage
t
0,5
0
Stage I Stage ll Stage lll Stage lV
II
I
Patients
. lnvolved regions:
Head and neck reglon . 7
Thoracic involvement: 4
Spleen: 3
Liver: 2
Abdominal involvement: 2
Bone marrow: 0
CNS: 0
lnvolved regions
8
7
6
5
4
3
z
1
0 I lnvolved regions
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Patients
. Mean CD4 count. 153,3 cells/mm3 (all 9
patients, range: 17-501 cells/mm3)
. Mean number of HIV RNA copies: 48,408
coples/ml (7 patients, range: 40-255,000
copies/ml)
ĺ
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HIV RNA - number of copies
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I HIV RNA- number of
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Treatment
. All 9 received chemotherapy:
3 patients CHOP
2 patients R-CHOP
1 patient COP
1 patient R-BFM
1 patient BFM
1 patient ABVD
2 patients prophylactic i.t. chemotherapy
. Median number of chemotherapy cycles 4,5
(range: 1-8)
12
Type of chemotherapy
3,5
3
2,5
2
1r5
1
0,5
0
I Type of chemotherapy
CHOP R-CHOP COP R-BFM BFM ABVD
Treatment
. Radiotherapy:
4 patients had additional
radiotherapeutical treatment with 30,6 Gy
. HAART.
8 patients received HAART, 7
simultaneously wlth chemotherapy, 1 after
chemotherapy
I
l
1 3
Type of treatment
10
9
8
7
6
5
4
3
2
t
0
I Type of treatment
Chemotherapy Radiotherapy HAART
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II
Comorbidities
. 1 reactlvation of CMV infection
. 1 latent TBC infection
. 3 hepatitls B infection in their clinical
history
. 1 patient had 2 other types of cancer
(invasive papilary carcinoma of urothelial
epithelium, laryngeal carcinoma)
14
Supportive treatment
. 6 patients received prophylactic antibiotlcs
and antlmicotics (combination of
tri metoprl m-s u lfamethox azol and
fluconazole)
. 6 patients received prophylactic
g ran u Iocyte colony-sti m u lati ng factor
Complications
. 7 had febrile neutropenia
. t had stomatitis
. t had CMV pneumonltls
. t had Streptococus bovis sepsls
.lhadDW
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l
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Complications
8
7
6
5
4
3
2
1
0
l Complicatĺons
Febrile Stomatitis CMV Strep. bovis
neutropenia pneumonitis sepsis
DVT
Conclusion
. 8 patients completed planned
chemotherapy treatment
. 4 patients received addltional radiotherapy
treatment
. 7 patients who completed planned
chemotherapy treatment achieved CR
. 1 patient died after 1st cycle of
chemotherapy
. 1 patlent died after completed
chemotherapy treatment
1 6
Conclusion
. 7 patients are still in CR on regular follow up,
mean time of their survival is 65 months (range
16-150 months)
. Mean time of survival of all patients is 52 months
(range 0-150 months)
. 1 patient died after 1st cycle of chemotherapy,
because of spread of lymphoma
. 1 patient died after completed chemotherapy
treatment, because of an opportunistic infection
Conclusion
. Patients were treated with the same
chemotherapeutic regimen as non-HlV
lymphoma patients
. Patients received HAART treatment
. Most patients received antibiotic and G-CSF
prophylaxis
. Patients in our clinical trial had lower stage of
lymphoma and different regions of involvement
than AIDS related lymphoma patients
I
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AIDS related lymphomas
Mesti Tanja,MD; Gregoric Brigita,MD; Horvat
Matej,MD
Mentor: doc.dr.Jezersek Barbara, MD, PhD
Objective
. Discuss the most important issues ln AIDS
related Iymphomas - what we, as
oncologists, should be aware of
I
l
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lncidence of AIDS - related and AIDS - Non related
cancers
Tho 1sth cohí.rcn€ on R€twiÍusś End oppońuniíĺc lníoc'tĺon6' 2008, Abstrac't 'l5' Fábń6 Bonngt lmmunodofici6ncĺ and R|Śk oÍAlD$d6íin|n9
and Non_AlD$d6Ínin9 cánB3: ANRS co3AqulteinÔ cohoń''l098 to 20m
Categorles of HlV-associated Lymphomas. WHO
Classification
. Lymphomas also occurring in immunocompetent
patients
Burkitt's lymphoma
Classic
With p lasmacýoid d ifferentiation
Atypical
Diffuse large B-cell lymphoma
Centroblastic
lmmunoblastic
Extranodal marginal zone B-cell lymphoma of mucosa-
associated lymphoid tissue lymphoma (rare)
Peripheral T-cell lymphoma (rare)
1 I
Categories of HIV-associated Lymphomas. WHO
Classification
. Lymphomas occurring more specifically in patients who
are HIV positive
Primary effusion lymphoma
Plasmablastic lymphoma of the oral cavity
. Lymphomas occurring in other immunodeficiency states
Polymorphic B-cell lymphoma
*HlV, human immunodeficiency virus
AIDS related lymphomas
. Burkitt's lymphoma
. Large cell lymphomas
. Primary effusion lymphoma
. Plasmablastlc lymphoma of the oral cavity
20
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AIDS related lymphomas
. NHLs are the most common lymphomas
. DLBCL comprises 30o/o of AIDS related
disease and is usually seen when
cD4<100
. 70o/o of lymphomas in HIV have mutations
resulting in deregulation of BCL-6 proto-
oncogene (pathway normally leading to B
cell proliferation)
Hypothesis
Lymphoma
B cellturnover
lmmune activation
HIV viremia
Viral co-infections lmmunodeficiency
t- .
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Clinlcal characteristlcs of ARL
, 80o/o present with Stage lV disease
. Diffu.se lymph node involvement is considered
mucn less common
. Gastrointestinal HIV related lvmphomas are the
most common localization (45o/o)
. Marrow involvement 30% of time thus consider
marrow biopsy if no other sites
. CNS involvement 1 0-2Oo/o
Discussion
. Risk factors
. The importance of HAART
. The role of rituximab
. Treatment
22
Alexander Zoufaly lnsufficient Virus Suppression during
HAART ls a Strong Predictor for the Development of AIDS
related
Lymphoma: German CLINSURV Cohort
Known associations with lymphoma risk
Study Associated
Kirk et al,Blood,2001 lncreased risk:
Age, male sex
Lower CD4 count
Higher VL
The15th confeĺencé on RetroVř!5es and oppoń0ntsťclníctions,2@, Ab*let 16
n r rus on unng
HAART ls a Strong Predictor for the Development of AIDS
related Lymphoma: German CLINSURV Cohort
Results [6364pts]
All lymphomas(n69) Burkitt's
(ní ĺ)
Non Burkitt
high grade(n32)
PCNSL(nB)
Significant in a multivariate analysis
Cum.viremia
<0.01
1.4(1.1 .-1 o.e(0.4-1.9)
ns<0.01<0.01
3.o(1.6-5.3) l l ĺ.s(ĺ 'ĺ '_z.o)
The 15th coníeren.e on Retrovhu'ésänd opFduntstl. lňf&tlons,2@,Ab*ret 16
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Alexander ZouÍaly lnsufficient Virus Suppression during
HAART ls a Strong Predictor for the Development of
AlDSrelated
Lymphoma: German CLINSURV Cohort
Conclusion
. Age, latest CD4 count, cumulative viremia are
strong risk factors for the development of
lymphoma
. Higher impact of viremia for Burkitt's lymphoma
. Viremia is the only directly modifiable factor
. Optimization of HAART might reduce the
incidence of lymphoma
The 15th coní.rcncéon Rôtreuŕus.nd oPFđUnbüclnfetlon'/ 2@l AbśÍđ 16
Non Hodgkin Lymphomas
lnternational Prognostic
lndex
Risk factors:
' Age
. Stage
. Serum LDH
. ECOG performance
status
. Extranodal site
Prognosis
. Low risk (0-1 points) - 5-
year survival of 73o/o
. Low-intermediate risk (2
points) - 5-year survival of
51o/o
. High-intermediate risk (3
points) - S-year survival of
43o/o
. High risk (4-5 points) - 5-
year survival oÍ 26%
24
Marc Bower, Prognostic index in ARNHL on
HAART, Chelsea and Westminster cohort
a 9621 HIV seropositive; 111 ARNHL
Two independent predictors of death
tPt
CD4 count
a
a
a 1 y survival: low risk 82o/o;
low interme diate 47o/o;
high intermediate 20%;
high 15o/o
Bmr M ét al; A ło$dlc lňd.rĺor$đmlc AlBful.t d Non-Bodtłln LFphom. hbd ln th. Ěrr ď ĺlthly Mlw ML.rourul Th.nł;
Annak oílnternal médlclre; AUr6t 1ą 2@5wl. 143 no.4 265_273
HAARI
. Reverse transcription inhibitors (viral RNA-
viral DNA)
N ucleoside reverse transcriptase
inhibitor (NRTI);interfering with nucleotides
Non nucleoslde reverse transcriptase
inhibitor (NNRT!); reverse transcriptase
enzyme
. Vlral assembly inhibitor
Protease inhibitors (Pl); protease
enzyme
25
Studies showing the impact of HAART on response rate and survival
Study (date) Population Study design Main findings
Tam (2002) United States
Multicenter AIDS Cohort
(MAc)
n=1 00
Retrospective
observational: ĺoo men
with a diagnosis of NHL
HAART associated with
lsurv for NHL pts
And 8% reduced risk of
death
Hoffmann (2003) Germany multicenter
cohort study
n=203
Retrospective
observational
HAART R associated
with f CR and OS
bÍl.t.l' nś.ńtÁdtfuólnfuquŕ.d lmmunodń.i.Ńysynd.Ôń.(Al05}-ídil.d LYmphm,
cA c.!.q J cliń 2m5) s5:229_2łr,d;10.3322ł.ntlin 55'4'229jo 2m5 Mťlt'n Gnlđ sci.N
Selected Regimens and Outcomes for AIDS
associated NHL
Regimen Evaluable MedianBaselino
Patients CD4c/mm3
4A 70
CRR
(%)
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PFF Study
(Ł"Í9ĺFI_q"J_ĺy 2y
36lnÍusionaI
CDE 'A'él;1lľiřä,ťćĺi a il","
Freelj
CDE(Cyclophosphamide,doxor
LiäldÍďleLtoposide); EPocH
([toposide,doxorubicin
Dose-adjusted
EPOCH (HAART
deferment until
chemotherapy mmplotion)
198 74
Threé pool€d
Phaso ll trials of R-CDE
74
99
51
'161 70
prednisone and bolus
cyclophosphamidel; HAART
(Hi8|Y ađive antirerovLal
9pi'Ísńl ElDE (Rtruximab
with CDt); R-CHOP
(Rituximab with
cvcloDhosDhamidé'doxorubjci
"]fif 
BłR{lPl'd pi"ani,o""
(cHoP)), R-DA-EPocH
(RitÚximab with dose adiusted
(DAl rpocH)
Sparano et
Randomized
R.CHOP
vs.CHOP
.6 50
4A
Randomized
al.
R-DA-EPOCH
vs.DA-EPOCH
follow€d by rituximab
1 80
38 180 72
Á.qutr.dlńňunod.füi.fti.l:B.rh.rdä,etó.l161ZtG
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R!TUXIMAB
Schedule Sample size CR (%) 2y OS (%)
Kaplan,2005 R-CHOP 99 58 55
Ribera,2008 R-CHOP 81 69 56
Abbreviations: NHL, non-Hodgkin lymphoma; CR, complete response; OS, overall survival;
R-CHOP, rituximab plus cyclophosphamide, doxorubicine, vincristine and prednisone; R-CDE,
rituxima b,cyclophospha mide,doxorubici ne a nd etoposide
',een_Phillppe spáno, Dominique costegliola. christine Katlame, Nicolas Mounier, Erlc oksenhendler, oavld Kháyat; AlDs-Related 
Mäli8náncies: state ofth€ An
and Theíapeutĺcchallenges;lounol olclinical oncologtr vol 26, No 29 (odober 10},2m8: pp' 4834_4842
Conclusion
. Factors related with neoplasms rather than HIV
variables are the maln predictors of treatment
response and outcome
. AlI HlV patients with lymphomas (Hodg[tn'ę ąld
non-Hoiigkin's) have to be treated with HAART and
chemotherapy simultaneously
. As in HIV-negative counterparts, R-CHOP should be
recommende-d as treatment for non-Hodgkin's
lymphomas. ABVD should be provided for treating
Hodgkin's disease
27
Conclusion
a Rituximab significantly improves survival of patients with
HlV_related non-Hodgkĺn's lymphomas, without
increasing mortality from infections
. Prophylaxis of opportunistic infections has to be done
while patients are receiving chemotherapy, even when
CD4* counts are > 200 cells/ml
. Primary prophylaxis of FN (20% risk) with hGFs
Conclusion
. Central nervous system prophylaxis should only be done
in subjects with the highest risk for developing neurologic
disease, such as in patients with Burkitt's lymphoma,
those with stage lV, and those with lymphomas of the ORL
area
. ln HIV patients with refractory or relapsed lymphomas, if
the clinical situation is good enough and it is decided to
proceed with salvage therapy, special consideration
should be given to autologous hematopoietic cell
transplantation
ln H|V-infected individuals, there is an increased incidencea
28
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MÁLIoNANT PLEURAL
MEsoTHELIoMÁ
(MPM)
Mojco Unk
Domen Ribnikor
Jono Pohole Golĺčnik
Bronko Zokotník
a tion Iesu
The correcŤ stotement is:
MPM is
t. a f reguent tumor (ĺnciden ce >
?o/100000)
2. aff ects mostly older Ťhon 60 years
3. good prognosis
4. most potients ąre ŤreąŤed wiŤh su?ge?Y
5. moinly deŤected in early stoges
2
1
Etiology ond epidemiology
' Rore tumor, ĺncidence obout I - ?/Io0000
' Moles
' Mesotheliol surfoces of coelomic coviŤies
(plauro , periŤoneum, pericardium, tunico
voginolĺs)
' Poor survivol (1 yeor)
' Azbestos (occupotionol exposure)
' Loten cy 40 yea?s (15-67)
3
Azbestos fibres
' Primory (- occupotiono!) ond secondory exposure
' Diseoses: ozbestosis, MPM, lung, ...
' Dose effecŤ relotonship but there is no treshold of
cummulotive exposurebelow which there is no risk
' All osbestos fibers ąre cąncerogenlc
. Chrysotile - white ozbestos
- 99% products
- 2-4x mo?e cancerogenic thon other typs of f ibers. Crocidolite
4
2
Slovenio
. osciloŤ|ng inc|dence in recenŤ yeors (between
?4 and 33 /100000)
. 29 new potients inyear 2007 (2óm,3f)
. 28% of potients from the Primorsko region
Rok v 5loveniji 2oo7. Ljubljono| onkološki ihštitut Ljubljano, Epidemiologijo in registar rako, Register rdka
Republike Slovenije, 2010.
5
Clinicol p?esentotion
' Symptoms shortness of breoth, poĺn,
cough, fotigue, weight loss , sweating,
fevér, polpóble mosses of the chest,
poroneop lostic syndromes
' occupoŤionol exPosur e to osbestos
. sĺgns of pleurol effusion
6
3
Diognosis
Chest X-ra}Ą uniloterol pleurol effusion or thickenin9
CT of the chest. ring like tumour olong the pleurol
covity, diffuse or no-dulor pleurol thicŘening
Th o ra co centesis f or cyto lo gy conf ormotion
(diognosŤic error)
Pleural biopsy (thorocoscopic- video osssisted
thorocoscopy-VATS , open surgery) for histology
conformotion (4 histologicol subtyps- epitheloild 60%,
sorcomotoid, mixed, desmoplostic)
Serum mesothelin relafed peptid QtulRP) and
osfeopontin
7
Questĺon 2
The co??ecŤ stoŤement is:
Serum mesoth elin related pepŤid is
t. A very sensltive biomorker
?. A specific biomorker
3. Useful in screening
I
4
Stogĺng (IMI6 clossif ication)
internotĺonol mesothe!iomo interest group
SŤoge r Io TIoNO
Ib TIbNO
T2NO
AnyT3, ony Nl or ony N2
Any T4, ony N3 or ony Ml
5to9e ff
SŤoge rrr
5to9e fV
R'usch af o|' A proposed naw internotionol TNM Śtagih9 śyśtsm for molignont pleurol masothelioma. From
the Intgrnotiohal Meso1heliomo InteřeŚt 6roup. Chest 1995:Lo8l1Ĺ22-8.
Trovis et al. WHo clośśificotion of fumours. Tumours of the lung, pleuro, thymus and heort. Lyon,
Fronca:IARC;2004 9
Treotment: surgery
extropleurol pneumonectomy (EPP)- rodicol, but Rl or debulking
p leurectomy / decorti cation- R2
- Stage f-IIf: odeguote cordioc- pulmonory function
ond technĺcol possibilities
' í'tage r: surgery or follow up untĺl diseose progression
. 5to9e rI-III: technicolly resectąble ore treoted with
trimodolity regiment (OP+RT+ChT), unresectoble ChT only
- Stage fV ond sorcomotoid subtype: ChT only
-'Polliotive pleurodesis or PleuRx@ ond porietol
pleuretomy
10
L.
5
Question 3
Survivol of poŤients following
completed ŤrimodoliŤy treotment ĺs
eguol for potĺenŤs with N0-1 ond N2
dĺseose.
1. yEs
2. NO
11
Suľvival accoľding to mediastlnal nodal staĺus (N2 dlsease) and completion of the entire
tľimodality reglmen'
90
IroEzo
'ř 
60
Ju) Eo
(l)'EĘ
(E
=30E
đ20
10
100
0 12
J, ruo.ĺ di3oagô, trimod.lĺty complotod
J ľot dioro!8e, trimodality not complotod
J Nz diseagą tlimodality complotod
J Nz diseagą t]imodállty not completcd
24364a
T'ime (months)
60 72
P- '00ü3
de Ponot M et al. Jco 2009;27:í413ł4'ĺ8 12
6
Treotment- rod íotheropy
Adiuvont rodiotheroov Ťo whole hemithorox after EPP for locoldiseose
co-lłfiol (8O7. locol ŕéccurence rote dfter EPP only ond 13% ofter RT
followin9' EPP)(50-ó0 6y)
sionif icänt imorovemenŤ in overoll survivol ofter EPP+RT (33.8 months vs.
1ďmonths; p : o.o+) ĺn eorly stoges (I_II) but not in stoges III_IV
Rusch eÍ ol. A ohose ľI trial of surqical reśection ond od.iuvont hiqh:do_sę i=emithoracic rodiation for
lňäiiljňoňł piäuiäl'lircóotháiomá. ĺ rhóio'c ćordiovosc 5ur9. 200l ocł:1244)l788-95.
ProphylocŤic droin siŤe rodĺotheropy (2t Gy)???
o'Rourke et al. A rondomiŚed controlled trial of intervantioh site radiotheropy in malignanf plaurcl
maspthaliomo. Rodiolher Oncol 2007 :84t18-22.
No improvemen_ľ ąÍter odjuvonŤ rodiotheropy followin9 debulkin9
pleurecTomy (R2), more toxicity
Boldini. Rodiotion theropy optionś íor molignanÍ pleuro| nesotheliomo' seminor Thoroc Cordiovosculor 5u19.
2OO9: ?tt!59-163.
Pollĺotive rodioŤheropy for poĺn relief (RR ó0%. durotion of response ?-
3 months)
13
Treotment- chem otheropy
. As neoodjuvont or odjuvont Ťheropy
(plotinum- bosed doublets)
' Unres ecŤable poŤientS stoge rr ĺn rrr,
sorcomotoid subtype ond sŤogeTv
. Plotinum onol ogues, f olate
ontimetobol itđs (pemeŤ reksed,
rolitreksed), gemcitobin, vin o?elbine ond
doksorubicin
14
7
Question 4
The wrong stoŤement is:
1. Combĺnotion cislpem is more eff ecŤive Ťhąn
monotheropy with cisplotinum.
2. Plotinum bosed doublets ore comporoble in Ťerms of
effictency.
3. Response rotes to chemotheropy arehigher thon
45%.
4. Potients without dispnoe do not need droinaoe of
p leuro! ef f usion bef or ä opp l i cot i o n of pemet r čxed.
Dickgreber et ąl. Pemelrexed sofety ond phormocokinefics in potients
with third-spoce f luid. Clin Cąncer Res. 2010 Moy 15;16(10):287?-80
15
Treotment- chemotheropy
ltt line
' Cgmbinotion Pemet?eksed/ cisploŤinum in
l't line improües overolt surviväl;
- I2.I m Vs. 9.3 m (P=0.0e) compored Ťo
single agent c isp loti num
- RR 4I % vs.76.7% compa?ed to single
agent cisplotĺnum
Vogelzang et ol. Phose III study oÍ pemeŤrexed in combinotion with cisplotin
versus cisplotin olone in potients with molignont pleurol mesotheliomo. J Clin
oncol' 20Ö3.; ?l|?636-2b44
16
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Treotment- chemotheropy
ltt line
' Combinotion pemet?eksed/ corboplotin:
- Ceresoli: medion survival 127 months
ond RR 18.6%
- Costoanetoi medĺon survivol 14 months
and RŔ 25%
Ceresoli et ol. Phose Ir sfudy of pemełrexed plus corboplotin in molignant pleural
mesothe I iomo. J Cli n Onco l. 2006: ?4:1443 -14 48.
coŚtaoneto et ol. Phose II sÍudv ol pemelrexed in combinotion with corboplotin in potients
with ňolignont pleurol mesothefiomol Ánn oncol. 2008;19l370-373.
18
I
Treotment- chemotheropy
1'* lĺne
' Combinotion gem/ cis:
- Von Hoorst: medĺon survivol 9.6 months
ond RR 16%
- Nowok: medion survival 17.2 months ond
RR 33%)
von Hoor.st et ol. Mulficentre phose II study of gemcitobine and ciśplotin in molignont pleural
mesoŤheliomo. Br J loncer' ?Ô0?:86:342-345. '
Nowok et al' Á multic€ntre phose II study of cisplotin ond gemcifobine for ĺĺolignont
mesothelioma. Br J Concer.'200?:871491:496.
19
Question 5
CisploŤinum ond corboplotĺnum ore
comporobly effective.
1. yEs
2. NO
20
10
Chemotheropy
cisplotĺnum or corboplotinum
Sontoro el al.Pemetrexed plus cisplotin o? pemeł?exed plus corboplotin for
chemonoive Dotienfs with rrioliononł pleurol mesotheliomo: results of the
Internotionäl Exponded Accešs Projrom. J Thoroc oncol. 2008;3 :756-7 63'
Comporison of cis/pem ond carbo/pem in
I7o4 potients conf irmed similor octivíty
(DFS ond t-year survivol); combinotion
carbo/oem is ą better choíce for
potíenťs Wíth Poo?e? Pe?formance
stotus ond comorbidity.
21
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Treotment- t arget ed Ťherop ĺes
Diff erent druqs hove been o? are beina
evoluoted (oloňe or in combinotion with"
chemoŤherbpy) -- Ťąrgeting:
- E6FR: gefiŤinib, erlotinib, cetuximob. PD6FR
- V1GF ond VEGFR: bevocizumob. sorofenib.
votolonib, pozoPonib, sunitinib, Ťol idomid
- histone deaceŤylose (HDAC): vorinostoŤ
- proteosome: bortezomlb
u'onlĄeerbeeck et ol. /tĄolignonf pleurol mesothe|iomo: The stondord of core ond chollenoes
for future monagement' črif Rdv oncol/Hemotol (2010)'doi:10.1016/ j,.critrevonc'2o1o'ő4'oo4
23
Question ó
There ĺs no benefit WiŤh Łnd ine
chemotheropy.
1. yEs
2. NO
24
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Treotment- chemotheropy
znd line
Phose rrr study compored pemeŤreksed single
ąaent in 2^o line'chembtheropy to best
sÚpporŤive cą?e in pemetrekśed noive
poŤlenŤs:
' signif icontly betŤer RR (18 vs. L.7%)
. signif icontly |onger time Ťo progression (3.7
vsl t.5 monťh; pí0.015)
' no improvement in overoll survivol (8.4 vs.9.7
months; P=0.74).
Jossem et al. Phase III łriol oł pemełrexed plus beśt supportive core co.mpored with best
*nĺ.e;ľlał[|ľľĺ:ô,loľ"*ed 
potienf 3 wiÍh odvońcbd mal i gnont pleůral mesothel iomo.
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Treotment- chemotheropy
znd ltne
Gemcltąbine ond vinorelbine show some efficącv in the
lst line chemotheropy --+ on option for o }ndline:
' ó3 potients treoted wifh weekly vinorelbin: RR 1ó%,
medion survivol 9.ó monthŚ
Stebbino et ol. The eÍÍicacv ond sofetv of weeklv vinorelbine in reloosed
mol ignoni p leu rol mesothel iómo' Lu ng ćąncer. zoog : ds,g ą-l
30 potient treoted with vinorelbin_oemcitobin ídov
1.,8:Q3)r diseose control in 43% Gď% PR ond 3š%'
sŤoble diseose), medion survivol 10.9 months
Zucąli et ol. 6emcifobine ond vinorelbine in pemetrexed-prełreałed potients with
molignont pleurol mesotheliomo. Concer:tl?:1555-t56t. ,,
Evoluotion
. Clinicol exominotĺon
' CT of the thorox after 2 to 3 c
chemotheropy (modified RECIS
criterĺo*)
Yc
T
les of
*
Byrne et al. Modified REćIST criterio for ossessement of response in molignont pleurol
mesothEliomo. Ánn oncol ?004|16;257 -?60.
28
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Conclusions
' Only o smoll proportion of patients might benefit
f rom aggressive interventions with rodico! or curotive
intent
' Effective, olbeit polliotive chemotheropy, increoses
|ife expectoncy ond helps Ťo relieve symptoms. Relievino svmptoms is the cornerstone in the
manageńeńt óĺ potients wiŤh MPM ot oll sŤages of
diseose. Enroll the patient in clinicol (prospective) study. Primory prevention ond targeŤed treotments ore the
future in monogement of MPM
29
I
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Modified REcIsT crit erią
Growth pottern of MPM (on CT of the thorox.sfericol chonges
for twoj dimensionol meošurements ore ussuolly not seen) -
CombinoŤion of one- ond two- dimensionol meosurements:
- oleural olooue ot the thorocic or mediostinol woll is meosured in two ploces, ot
leost 1 crh inłervol. three cuts on fhe CT chesf exominotion, the sum of the six
meosurements is d'efined os one-dimensionol meosurements of pleurol chonges
lesion ore conventionol RECIST criterio
iol response
ond
survivol (15.1 m to
reseorch to
nfo regu proctice
Byrne et ol. ńłodÚied REđIsT cfiterio Íor asseśśemant of response in molignant plaurol mesothelioma. Ánn
oncol2004'|1Ż257-26Ĺ
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Malignant pleural
mesothelioma
Clinical case report
Domen Ribnikar, MD
Jana Pahole Goličnik,MD
Mojca Unk, MD
Mojca Juvan, MD
Mentor: prof.dr. Branko Zakotnik, MD
6' Dlo' 12.,í3' 11'2oo1o
September 2006:
. 2 months dyspnea on exertion, epigastric blunt
pain
- family history: no malignant disease
, no (family) exposure to asbestos, ex smoker
Physical examination:
- PS (WHO) 1, subfebrile
- auscultatory dullness on the left, up to 6th rib
6. DlO, 12.,13 11.20010
a,
2
N.B ?, 1973
1
I I I j t, ' tir I 't, : 
: I ' :
blood count: WBC 1 I ,0 G/|. platelets 411 Gll,
normal Hb, CRP 54 U. normal renal and liver
function tests. no electrolite disturbances
chest X-ray: pleural effusion up to 6th rib
diagnostic pleural paracentesis: exudate. no
evidence of malignant cells
blind needle biopsy of the parietaĺ pleura. non
specific chronical pleuritis with hyperplastic
mesothelium
' histology mesothelioma, epitheloid
CT of the thorax (4 9 2006)
VATS
type
2
t
t
I
Multidisciplinary tumor board opinion:
chemotheľapy with gemcitabine and
cisplatinum, then opeľation
Planned: 4-6 cycles of gemcitabine (25Omglm2
in 6h infusion, day 1 and 8) and cisplatinum
(BOmg/mZ, day 1) O3W
Recieved: cisplatinum 3x, gemcitabine 10x
Toxicitv:
transient hepatotoxic effect of chemotherapy
(AST, ALT elevation 4 x IULN)
alopecia G2
mielosu pression (neutropen ia )
6 t)to 12 i3 ii ?,00i0
jlĺ,i:iilĺil'',l]i'
i
ĺ
3
January 2007
Clinically - absence of symptoms
CT (17 1 2007) Partial response (almost
complete regression of the tumour mass)
Multidisciplinary tumor board opÍnion:
technically inoperable - follow up
l,l
4
July 20OT
constant thoracic pain on the left (asymptomatic
with NSAIDS)
CT (September 2OOT).left sided pleural effusion,
visceral + parietal pleura thickening
prog ression
6 DIO i2 13 11 2OAi0
j ,,]łl łrlĺ/ 'i ]ll
5
1 radiotherapy
2 second-line chemotherapy
3 best sr-rpportrve care
6
- the patient did not decide for treatment
immediately --- follow up and supportive care
. CT (February 2008): spontaneous remission
- May 2008. pleuropneumonia with pericardial
effusion -+ antibiotics
. December 2009: Horner's syndrome, pain in her
left shoulder
6. DlO. 12.,13. 11.20010
Follow-up
Second line chemotherapy?
- 1 . reinduction gemcitabine-cisplatinum
, 2. pemetrexed-single agent
- 3. pemetrexed-cisplatinum
, 4. vinorelbine
- 5. gemcitabine
- 6. None of the above
6. Dto, 12.,13. 11.20010 14
7
Second Iine treatment
January 2010'.
- 5 cycles pemetrexed + cisplatinum, 6th cycle
pemetrexed only
- side effects of cisplatinum (hearing ĺoss and
paresthesias of the hands)
- cummulative dose of cisplatinum: 1070 mg
6 Dlo 12 13 11 20010 15
Treatment evaluation after 2nd line ChT
. clinically: no pain, no use of NSAlDs, persisting
Horner's sy and auscultatory dullness
l66 DIO r2 13 1t 200 l0
- radiologically
I
6
I
l
it
l1
l
I
September 2010'.
- progressĺve pain, Horner's sy
- raising platelet count, Hb levels stable
- Ultrasound of the abdomen: minimal ascites,
celiac lymph nodes susp. enlarged
t96 DtO. 12.13 11 20010
Follow up
'l) toxic effect of gemcitabine
3) reactive - due to anemia
6 DtO.12..13.11.20010
2) paraneoplastic
Thrombocytosis
20
10
iii11t tf t tt
mc änd Multophilcounl
i'ť'ť'ťťt
Platelets, Hb, WBC and Neutrophils during her
disease course
2'l6. DlO, 12 ,13 11.20010
GC GC CC
Sept.
2006
Sept.
2010
- 1. best supportive care
, 2. radiotherapy
- 3. 3rd line chemotherapy
. 4. targeted therapy
6' Dlo, 'ĺ2',13' 11.20010
Next step?
22
11
Benefit of lstline chemotherapy
Unpredictable course of disease - spontaneouls
regression, infections
Benefit sf )rtct line chemotherapy
The aim. to keep the quality of life (throughourt
disease course part time job, physically active)
r: DlrJ i.l ir Ii :l:j,
{ 't)ĺ;{;l{l'i ,ĺrlĺĺ ]
I
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TIME SAVINGS ASSOCIATED WITH ONCE-MONTHLY C.E.R.A.: A TIME AND MOTION STUDY CONDUCTED
lN DIALYSIS CENTERS lN ITALY FRANCE AND POLAND
W Klatko,l G Villa'z JC GIachant,: E De Cocką
TH-PO47'l
Boche
!NTRODUCTION
. Anemia is a common compliction ofchťonic kidney disease
(cKD) contributing to morbidity, mortalĺty, and ŕedu<ed qualĺty
oí life in thes patients.l
. Er}łhroPoi6isdimulating agents (Esfu) have ben a key
development in the tÍeatmentofanemia in Patien8with enďstage
íenal di*ase (ESRD) on hemodialysis. Esfu such as epoétin alfa'
epetin béą änd daŕbepoetin alfa have relatively shoít halfłiveś
and ŕequireÍÍequent adminiíBtion, Énging fro thre times a
wekupto on. every2w kto mainbin patients hemoglobin
{Hb)levelswithinthereco mended'getÉnge.'
. The .ontinuous eŕythŕopoiétin receptor ađittor (c.E_RAr) ha!
ben proven tosmoothlycorđ anemia änd maintain Hb levels
within the desired target Enge when administered once monthly
(Q4w) in p tienB with cKD both o oŕ not on dialysis.ls
. Anemia managementin CKD istime consu ing bothfor
healthere profssional' and patients. A hajoŕ chällenge for
hemodialysĺś centerś iś to imprcve eÍÍiciencywhile mainbining
high standaŕdsofquality and crefor patients.
OBJECTIVES
a To quantiry and co pare healthGre peEonnel time for frequent
routine anemia management-related task in hemodialysis
centeBfoŕ maintenance theEpywith both shofter-ading
ESA5 and C.ER-A" Q4W.
. To odel time 9vings foÍ a 1 0096 uptake of c'E.Rn. Q4W in
centeís across thre Éuropean countries.
SAMPLE
a This study was conduđed in nine dialysis cente ácŕoss thÍeé
European countŕie!:the aenteŕs ch in ltaly, Fcn(ą and Poland-
METHODS
a This Ms a multi<ountry multicenter, prośp đivą obseilationa|
śudy using time and motion methodology to delcŕibe
proceses and dfrument the time taken by healthcare śaff
to peŕoŕm fŕequent EsA adminiíŕation-related activiťes.
. The íudy Ms non-inteďentional as patients were treatałd
accoldĺng to individual center p ađice'
. NopatientdemogtphicswereCollđ dandalldataWeblinded
to pr srve the anonymĺty oÍ individual' paŕicipati g in th íudy.
Aremiamqđ taffites
. Theprftesses as9ftiatedwith cuŕŕentanemia management
were identifi d through intervies with centeŕ heahhrre íaff.
- ob ryed taslś were fuquent and obÉryable äđMtĺés sciated
with EsÁ treatm nt foí which time could be cleaĄ measured
and E not intefuined with he odialysis{elated ađivities.
-obęryed uśks in<luded pÍepaÉtion, diíŕibution. and
injđion of Esfu. as well aś Éo d keeping.
a Foí ęlected anemia management task sepaBte smples were
colleđed foŕ patienB r*eiving tBditional EsAs orC.E'RA
Target gmple sizes ď4o obseruations for activities per patient
(e9 inieđion) and 20 obtMtionsforađivities pergroupof
patients (e9 preparation) rere Collđed.
o Taskreŕeobseiled bytŕained designated obśerueŕs using a
stopwatch and time Ms Eoíded onto caę reporl forms-
a A weighted number of EsA ädministEtions per patient per )Eať
reŕe calculated in ea h centeŕ ba.ed on the ditribđion of EsA
prcduct5 u*d and injeđion frąuenry by EsA product
(obtained íŤom interyiews with healthcare ltaff)_
a Timedata wereanabżed using sAssoftMre assu ing a ga ma
ditribution and íatistiś were @lculated for each taśksample.
a Average time peí EsA-treated patient and the íÍeque cy
difribudon of injections at ea(h center were used to eśtĺ ate
the tob| time gvinqs that <ould be achiered with ä ] 009
uptake oÍ C.E.RA Q4W.
a The main sfudy end point time per patient per EsA sesśion,
@s u5ed to @lculate the annual time per patient péícenter_
RESULTS
Ch acteilsdśof hmodlolylsentars
a The numbeÍ of patie tś with ESRD receiving EsA treatment
atthetime of interuie$ nged fŕom 5Ĺ90 in lblian,3t7
in FÍench, and 60-136 in Polish centeÍs crable ]).
. The prcpo ion of C.E.R-A. uptake across hemodialysis centeB
in thíee European countŕies at time of inteiliews ŕanged from
2Ą-4aoin |ta|ian,2649% in FÍench, and 22-3496 in Polish
centeŕs Ctable l ).
o The number of EsA ini*tion! peí country per \@k ctegoÍized
by EsA type and route ďadmini'tration are shown in Figure 'l.
o The ave69e number of EsA injđionŚ peŕ patient peÍ yeaŕ foí
tÍaditional EsA produś Ms 'l03 in lblian,89 in Fŕench, and
93 in Polish centeÍs.
. The avenge numbeÍofC.E'R_A. injđĺorc peŕ patient peŕ lEaŕ
was ] 2 across ltary and Francą and 'l3 in Poland.
FlguÍ. l . ilumb.Í .nd tyF oÍ EsA in'điđ. Fí (6r.ŕ Fŕ wét
Obsered tlre pu patlent per yw
o Eíimated obserued ti e per patient p r ) ar acos thre
European countries nnged írom 9] to 38o min for EsÁs
and from l 2 to 68 min foŕ c.ÉR"A. (Figure 2).
FlauŘz tsÍ Faí by (mt.Í |mtn)
tooK thlyĹEnÄ
. Average reduđions in time when @nvefting a pätient from
tEditional EsAs to cE'RÁ_ Q4W rere si ilar across all <ountrjes.
and 85% in Polish centeEwerefound (Fiqure Đ.
,toddlngthe lmPact oÍ once-m thly C.ER.A. atthe
@ter lqet
. The reduđions in obsrv d ta5k frequencies follolung conversion
ofa l 00% uptake ofC.E.R.A. Q4W prcduced estimated annual
time vings of 87- 8% (8+2'] 7 hoUF) ĺn ltalian. 7H6%
(7G-109 hours) in French, and 82-88% (221--477 hours) i
Polish centeB (Figu e 3).
coNcLUstoNs
. Datatomhemodla}yslsc nt 6ercsthreÉmpean
@ntĺl6shomdthata 1(x'9 uptakeof cEnÁQ4w
maÍrt mnclh.npycou|d ofieĺsubstantĺal annua|
me savlĺrg6 on ŕequ nt änemle memgerent taskt
. TlE per@un y Bultsfoíťm savlÍĘr ľaĘ d fbm
8H896 ln lblĺaÍ' 7l-8 9t ln F mĘ aÍÉ 82-88% ln
Pollsh ente6.
. Admlnistľa on ď 12 lnje<tlons ďc.E R^ PeÍ Patlent
pel par mdd aĺoľ *arc health(ae muÍG to b
nä[Gt d !oo H lmpoítam cKDth Bpy n ds and
impftnE đrenll patient đe
o Th* Ísułts at ln lhewlthfindhgśŕom o ď
cąĺ lg wherc th|ĺ obsemtlonal studm Cďdxtd'
shov|ĺrg ct|ĺnabd annual tlm gingE fu lląYiÍĘ a toĺ)96
uptake of cE-RÄ Q4wď6s&49 ffittre cnteB ln
spah andď79-9t96ffi fouľCenter lnGennany.
. Th se ĺesufts oníÍm data ŕďn PŘvlous đre and
modon studĺg orrled out ln enteÍs aCÍ6 Ge'maÍry, th
usĄand th uKwhlch shotmd thet m EsA admlnlst cd
Q4w rculd oŕŤeŤ annual tlm 9v|Ę5 of 79_8496.''
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moliignont tumors ore only sporodic.
2
I
I
Pheoc
3
li
l.
R.lloblllty
Diagnostic of molignoncy
4llĺlđl đĺłiľlo
Weight loss, feminizotion,
nodal ond di3tohÍ metostośeŚ
poÍltcLtb ond a]'.tlc
ô.lĺtl.lo
Tumor weight> 1009, tumor
necrosiś, fibrous bronds,
vośculor invosion, number of
miloseś per high_power field,
p53 mutotions
Consistent with molignoncy Virilism, lushing's virilism, no
hormone produďion
Nucleor pleomorphism,
aneuploidy
Suggeslive of molignancy Elavated urinory 17-
kstośtaroidś
copśular invaśion, inhibin, 21_
hydroxylose deficienry
Unralioble l-łypgrcortisoli5m,
hyperoldosteronisłĺr
Tumor giant cells, rytoplasmic
śize voriotion, rotio betwaen
compact and cleor cells
ednn.lĺhíld
2
mdUlr
gynecomostio
. High DHEA-S suggests ACC
. Áldosteron sec?eting (rare)
ąrlbol
dló,olr
4
l'
I
(-'1
I
I
DbL2
sđry {íttm for ádffiÍtlol eElnma (Áac1prep.d ĺĺ t!-unlon
lÜopm N.hrcÍł( fđ ó. sfudy oÍÁdEnal TUmu (ENSAD 2m&"_
htmrllomL cdlü! oreĺ (utc) zĺ'oa üd
T1' ímđľ ś5cmi iIą tmoÚ >'m; T3' tumu lnlllE*lon ln sÍmuÍj|ntÚsa: T/ĺ
(!NSAT; rl9 rcnout ülmour tbrcmbÚ in Ena W./EDJ vcln} tlo' no pośtlE lymph
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ttmr ĺilülon ln adráGnt oÍtan5
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tÜmĺ'-ílBo ll9ouřďlĘ
dl86Ea
p.oSraah,"tuÍÍnt.Íggrądon /
stÓlodboar.
folbľ{p c\r€ry 3 montľr
imggkĘ aĺrd tuĺrpÚ m9.ł9ĺa
foĺow{p slrory 2 ĺnonth8
nď8u@t!íJlauccolsńrI notp6'|üoo.
in@Írťgtg ĺ9lolbn
coĺťeb Íłoc,üon
tvStagB Hll
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Carney - Stratakis dyad oxtHđBnal 
prnganllloma ł olsT
Cafney triad (autosomal domlnant
sYndDno)
oÍmđrend pan!ügliom. ł olsT +
pulmonary ohonđrcml
Neurďbľomatogls type l
(íoÍt!.Íly von Roai|lnohaúson dlffi '-
5096 autosmal domlnanttrđo
ĺ ĺipnďlóĺ ńbuibllnrómm
(negatlve regulator of RAs
oncogene)
.đEndh
bsnlgh,
lr
L
L
!
t
I
weĺ9hmore
moÉ mitos€sL'€'Śś
ll^ÍB-1 oneuploidy,
profiling
high S_phose fraďlon
6ene enpncssion
7
,
sccnniR;g, ocŤ?eoscon, PET
I
I
JANUARY 2OOO
History: ?9-years old women
presented wĺth sĺgns of
hypersecretion of cortisol and
androgens (Cushĺng syndromo,
hĺrsuĺtism, thĺnnĺng of the skín
with bruising, vĺrĺlĺsotĺon with
deepening oÍ the voĺce ond
omenorrheo, psyhologĺcol
dĺsturbonces)
Physical exdmination: acne, mole hoĺr pottern,multiple
bruises of the skin, otherwĺse b.p.
Lab.findings.'complete blood count, renol ond lĺver
tests:normol, K: 3.4 mmol/l J
ádÍrnal elerd
2.3
c',t&,ol
dńÜl'ono
MORPH OLO GTC EV ALUATION
' Chest X-ray: normol
. Us/cT abd.: 8 cm heterogeneous tumor in the rĺght
suprorenol glond with irregulor morgins, poorly
cĺrcumscribed, wíth some colcĺfĺcotĺons, dĺsplocing v.covo
ĺnf., poncreotic heod ond duodenum, but wĺthout locol
ínvosĺon or lymph node ĺnvolvement or other metostoses:
ACC susp
. cT łhorax: no sígns of metosŤoses
metastatĺc sĺłes ofĽ 'Lung
ACC,
the sŤaging Acc
and liver
and thoracic scans integral ofI
{r
I
Ť
I
normonal worK-uP ano lmaglng ,n PaÚenrs wltn susFnctu or proven Avvrecommendation of the ACC working group of ttre
European Network for the Study of Adłenat Tuĺnors (ENSAT), May 2oo5
Hormonal work-up:
Glucocorticoid excess
Dexamethasone suppression test (1 mg, 2300 h)
Excretion ofÍŤee uńnary cortisol (24 h urine)
Basal cońisol (serum)
Basal ACTH (plasma)
Sexual steroids and steroid precursora
DH EA-S (serum)
1 7-OH-progesterone (serum)
Androstendione (serum)
Testosterone (serum)
17-estradiol (serum, only in men and pos1menopausal výomen)
Mineralocońicoid excess
Potassium (serum)
Aldosterone to renin ľatio (only in patients wĺth arterial
hypertension and/oľ hypokalemia)
Exclusion of a pheochromocýoma (1 of 2 tests) catecholamine excretion (24 h urine)
Meta- and normetanephńnes (plasma)
lmaging
CT or MRI ofabdomen and thorax
Bone scintigřaphy (when suspeďing skeletal metastases)
cłrola!taÍol
Ęl
Al&ate ŕona Fąlłtway
HoPtĄoNAL WopK-UP
1.Assessenenŕ of glucocorŕĺcoid excess:
* dexameŕason suppresion test (2 ng): no cortisol suppresion
* basal cortisol level (serun):1465 nnol/l
* basal ACTH level (plasna): normal 5.2 pnol/l
2. Assessment of sexual steroids and sŕeroid Precursors:
* DHEA-S:124.0 pnol/l
* 17-OH progesteron: 132.7
* Androsŕendion: I14.5
* Testosteron: I 58.7 pnol/l
3. No mĺneralocortĺcoĺde excess
4. Exclusion of pheocromocĺtoma
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PRIMÁRY TREATłI^ENT
28.1.200O:'
Histology: ,the cancer
cells with ?ote,
iolymphoticotypicol
invosion ond
Hormonolly
(sŤ IIr), R0
11
,
*
* Basaĺ
* Basal
2.
*
*
rl.
*
giÉ'l ! ll !'! ! j ! ! !
ĺ
I
I
*r Jtkrnrtaa
I
I
I
I
'rmbFS (42 months vs 10, p<0.001,,42 vs 25, p=Q.QQ5;
*mOS (110 months vs 52 , ps0.001, tt} vs 67, p=0.10)
Terzolo M, eŤ ql. N EnglJ Med2007
recommandedtułnôn
resection
1 2
l-t
ľ;
t
J-r
j
ll
ll
ĺ'l
.L
* pottern
TREÁTMENT(cont)'.' j'
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*
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a
FOLLOW UPz OOTOBER 2OOI
(10 months ąfter inĺtiotion of treotment)
, History,
o
,
testo
. CT and
recu?
. CT thorax:2 'metostotic luń9 nodes (4 mm) in left
lower lung lobe
14
ĺ
ĺ,
I
I
I
t,
Tf surgery is not feąsible, pts should be'freaIed li]ke'pt!
with mżtostoŤic diseose (miŤotone+ /-cyŤotoxic Ťheropy)
i
ĺ
I
l,l
1l
[,
t.l
,l
,ĺ
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a
Regulor 3 monthly follow-up
1 6
JUNE 2@5
AsympŤo Smoll
(lcm) I
US obdo
í)
ä
WHAT KIND oF TREÁT ENT WOUL you
a
a
a
a ton
. 5. resectĺon of metostosis ond chemotheropy
17
TREAT^AENT OF ?.nd RECURRENCE
. 30.ó.2005:
. CTsconof no
rodiologicol
. 15.7.2005
5 9 doily),
titroted to
đ
a
a
. PoŤient b.enefiŤed from previous mitotone Ťreotments by
possible lenqtheninq of brevious recurrences with
pgstoperotiÝe use iń the p_qgt Gfter initiol resection ?o0o,
äf ter' metostotectomy i n' 200 1)
18
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I
I
ĺ
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ĺ,
FOLLOW-UP AFTER 3 MONTHS
. Hormono!
. CTthorox: radicol with
no suspt nory
Iobe ond no
right pleu
' No other
(5z) plus nĺtotanc (sz/ru (Khan cł al, Ann of oncology
ofterwords
nĺinductio
Słłtoŕozołocln
2oro)
L-5r tg Sz/d
Sz every ?I days
*ongoing first rondomĺsed, phIII triąl in ACC (FIRM-ÁCT)
ĺ,consider enrollment in o clinicol Ťrio|!
19
a
a
Occosional tumor havebaąn reported for the
ontiongiogEnĺc coumpound tholidomide (Chocon R eŤ ol.
Journol of Cllnĺcol oncology 2005)
TREÁTMENT(metostatic
disaose)
. MitoŤon
D 2-4)
+ cisplotin
' Evoluotion
pleurol
meŤosŤoŤic
. Surgicol procadure recomanded
20
đ
1
?1,3 week
by surgery
cyclas n otŤempt to reduce tumor mqsŚ
TREAT^ĄENT (DTlc*copecitobin+imotinib)
(19.1.2@6-8.3 .2@6)
' AfŤer I.
odversa
no serious
. EvoluoŤions n of pleurol
ic siŤes
. 12.4.?006z
Gv)
thorox (ó0
I
l
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FOLLOW -UP
(5 months loter)
US obd: progression in the obdomen with o bulky
metostotic mosses in the obdomen
(r et roperitoneum, peritoneum, omentum)
. Triol with tholidomide 2OO ngldoily ond mitotone
(g/daily) (Chocon R et ol. Journol oJ clinicol oncology 2005)
. Control U5: progression in the obdomen ond new
lesions in the liver (37x 30 mm in VII segment, 33
mm V rr segment), ciŤologicolly confirmed
. 24.tl.200ó: Surgery with excision of bulky mosses
in the obdomen ond RFA of liver metostoses
TREATMENT (cont)
. After 1 month: CT thorox ond obdomeni progress in the left
lung, mediostinum, thorocic woll, obdominol progression
. Theropy with Ťholĺdomide ond miŤotone stopped
. 6.2.2007: exPloraŤory loporotomy with odhesiolisis,
metostotectomy in the liver, mesenterium, pelvis, colon
. After surgery: ocufe respirotory distress with citologicolly
negative pleurol effusion with mediostinol displocement
. Potient wos put on supportive theropy
22
mitotane vs mitotane+lMC-41 2
sorafenib and metronomic paclitaxel
sunitinib
mitotane vs observation
EAP-M vs Sz-M
multiple TKI
(phase ll)
acljuvant r.nitotane after R0
resection (phasc lll)
establishlnellt of a first linĆ cytotoxic dľtlg
re<lirrert (phasc lll)
lGF-Rĺ antibody in addition
to rnitotane in first line
systelnic treatnletrt
(ranclomized phase lll)
rnultiple TKI in cornllination
With lr1etroĺrolrric cht (phase ll)
i
l
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ľh9 no denivalotion of
24
i
t
['
lili
lr
Il1
l,llr
Pnu[YnEAItEł{ľt gl,RvlüLAł{0E|
ĺ2tnoFÜttsch|
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ü'm-odBml pomaoĘllom + 6IsT
(outośoml domimnĺ'yndrone)
Carney - Strotokis dyad
qtm-odBrol pomaongllorE + 615T +
pulnomry chondĺom
Corney tfiod loutosonol domircnt
gyndľoĺp)
l\lrwoflbomś ł shrcnnom' ł
murofibIoffcom3 ł @f? ou loil ślots +
optic allohoś ł ogtrocyłomg +
phrcfuut'ocytom (o,ĺ _5,7ŕ, bobn.
odŇno|ln tsŇtltE' .'.
A gene for neurofibromin
(negotive regulotor of RÁs
oncogene)
Neurof ibromotogis type I
(forncrý rcn Řackllnghou*n dig* -
50% oulosml dmimnt tmit)
!l'!lLltĺ!uĺ'$uq 1 .ňB.elw
ĚüiĘaółĺli'fuöl ()!0r ildb'Ełt,
dopolnln. or nmdÉmlln ď odil'olĺn
ninťidśuccinote dehydrooe'nose)
A SDHä, d anď D (gengg for',,ł
diffeí.nt śubunĺłś of
f oLlBą]đtfi {łFiňĺĺĺäi,Ťffi&đôfiÄ''|ýĺďľonłr) 
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16ü!.!g@,9!!. l.|ccN cllnlcol Pťqďicg ouldlll ná ' \!2.2010
uuůr@9!ĺggr. NcI ph@chronocytom ond Porcgongliom T.@im!nt.
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